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FENOTIPIZZAZIONE DI PAZIENTI CON LAM SPORADICA E SCLEROSI TUBEROSA: 
DALL’ANALISI FUNZIONALE ALLA VALUTAZIONE BIOCHIMICA 
 
Riassunto 
La linfangioleiomiomatosi (LAM) è una malattia rara sistemica che determina lo sviluppo di 
cisti aeree multiple all’interno del parenchima polmonare, di linfangioleiomiomi sia toracici che 
addominali e angiomiolipomi renali. Può svilupparsi in una forma sporadica (S-LAM) o come parte 
del Complesso Sclerosi Tuberosa (LAM-TSC), una malattia genetica autosomica dominante che 
causa la formazione in pressochè tutti gli organi corporei di neoplasie amartomatose. Solo da qualche 
anno è disponibile una terapia in grado di ralletare la progressione della LAM.  
Il programma di dottorato della Dr.ssa Silvia Terraneo è stato concepito con lo scopo di 
espandere la conoscenza su aspetti ancora poco noti della LAM sia dal punto di vista clinico (diagnosi 
e follow up) che dal punto di vista della patogenesi e che sono riportati nella presente tesi. 
Come primo approccio è stata effettuata una valutazione delle caratteristiche cliniche e 
genetiche delle pazienti affette da TSC con e senza coinvolgimento polmonare seguite presso il centro 
per la diagnosi e la cura della Sclerosi Tuberosa dell’Ospedale San Paolo. E’stata indagata una 
possibile associazione tra LAM e altre caratteristiche della TSC; è stata inoltre condotta un analisi sul 
possibile ruolo diagnostico degli esami di funzionalità polmonare, nell’ ottica di limitare 
l’esposizione delle pazienti alle radiazioni ionizzanti della TC del torace. Il risultato dello studio ha 
dimostrato come la prevalenza della LAM nelle pazienti con TSC aumenti con l’età. A causa della 
disabilità mentale presente nella TSC, la funzionalità polmonare è stata eseguibile solo in una parte 
del campione analizzato e non si è mostrata utile nella diagnosi della malattia, il cui gold standard 
diagnostico si è confermato essere la TC torace.  
Nel contesto della valutazione clinica delle pazienti con LAM-TSC del centro, è stato descritto 
il caso di una paziente con TSC LAM che durate il follow up ha sviluppato altre 2 malattie rare: 
sindrome da overlap epatite autoimmune/cirrosi biliare primitiva e sarcoidosi; è stato speculato un 
possibile ruolo del pathway mTOR e  MAPK, ben conosciuto per TSC e LAM, nello sviluppo di altre 
malattie, quali ad esempio la sarcoidosi.  
Nell’ultima parte del percorso di dottorato sono stati analizzati i dati derivanti dal dosaggio su siero 
di 4 biomarcatori (VEGF-D, VEGF-C, MMP-2 e MMP-7) nelle pazienti con LAM, sia S-LAM che 
TSC-LAM. Lo studio presentato in dettaglio nel testo, conferma il valore diagnostico del VEGF-D 
e mostra una possibile utilità del MMP-2 e MMP-7 come biomarcatori di malattia.  
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WOMEN WITH LYMPANGIOLEIOMYOMATOSIS: FROM RESPIRATORY FUNCTION TO 
SERUM BIOMARKERS ANALYSIS. PHENOTYPING OF A RARE DISEASE. 
 
Abstract 
 
Lymphangioleiomyiomatosis (LAM) is a rare progressive cystic lung disease that affects almost 
exclusively women. LAM can occur sporadically, or can be associated with tuberous sclerosis 
complex (TSC); a rare disorder with multiorgan involvement effecting the brain, kidneys, heart, liver, 
skin and eyes and is associated with intellectual disability, epilepsy and autism spectrum disorders. 
Dr.Terraneo PhD project was developed with the aim to expand clinical knowledge about diagnosis 
and follow up as well as to analyze pathogenic aspect of the development of the disease.  
 As a first step of the PhD project, the association between LAM and other features of TSC 
(e.g. demography, extrapulmonary manifestations, genetic mutations..) was investigated as well as 
the role of pulmonary function tests (PFTs) for LAM diagnosis. Our results demonstrate that age, but 
not PFTs, is independently associated with LAM development in patients with TSC. PFTs, even if 
indicated to assess impairment in lung function, result feasible in a limited number of patients due to 
cognitive impairment, and are not significantly useful for LAM diagnosis in women with TSC. 
Successively, the case of a patients with coexistence of three rare diseases (autoimmune 
hepatitis/primary biliary cirrhosis overlap syndrome, lymphangioleiomyomatosis/tuberous sclerosis 
complex (LAM-TSC), and sarcoidosis) was described. We speculated that the dysregulation of the 
pathway involving mTOR and MAPK and their interaction might play a role in the pathogenesis of 
diseases other than TSC, including sarcoidosis. 
In the last part of PhD project, the serum levels of VEGF-D, VEGF-C, MMP-2 and MMP-7 were 
assessed in a cohort of patients affected with S-LAM and TSC with and without LAM.  
Our results showed that VEGF-D, MMP-2 and MMP7 were higher in patients with LAM than in 
patients without. VEGF-D was confirmed as the biomarkers with the highest accuracy for LAM 
diagnosis. MMP-2 and MMP-7 could be a promising biomarker of LAM.  
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CHAPTER I: USEFULNESS OF PULMONARY FUNCTION IN THE EVALUATION AND 
FOLLOW UP OF PATIENTS WITH LYMPHANGIOLEIOMYOMATOSIS. 
 
WOMEN WITH TSC: RELATIONSHIP BETWEEN CLINICAL, LUNG FUNCTION AND 
RADIOLOGICAL FEATURES IN A GENOTYPED POPULATION INVESTIGATED FOR 
LYMPHANGIOLEIOMYOMATOSIS 
 
ABSTRACT 
 
The advent of pharmacological therapies for lymphangioleiomyomatosis (LAM) has made 
early diagnosis important in women with tuberous sclerosis complex (TSC), although the lifelong 
cumulative radiation exposure caused by chest computer tomography (CT) should not be 
underestimated. We retrospectively investigated, in a cohort of TSC outpatients of San Paolo Hospital 
(Milan, Italy) 1) the role of pulmonary function tests (PFTs) for LAM diagnosis, 2) the association 
between LAM and other features of TSC (e.g. demography, extrapulmonary manifestations, genetic 
mutations, etc.), and 3) the characteristics of patients with multifocal micronodular pneumocyte 
hyperplasia (MMPH). Eighty-six women underwent chest CT scan; pulmonary involvement was 
found in 66 patients (77%; 49% LAM with or without MMPH, and 28% MMPH alone). LAM patients 
were older, with a higher rate of pneumothorax, presented more frequently with renal and hepatic 
angiomyolipomas, and tended to have a TSC2 mutation profile. PFTs, assessed in 64% of women 
unaffected by cognitive impairments, revealed a lower lung diffusion capacity in LAM patients. In 
multivariate analysis, age , but not PFTs, resulted independently associated with LAM diagnosis. 
Patients with MMPH alone did not show specific clinical, functional or genetic features. A mild 
respiratory impairment was most common in LAM-TSC patients: In conclusions, PFTs, even if 
indicated to assess impairment in lung function, are feasible in a limited number of patients, and are 
not significantly useful for LAM diagnosis in women with TSC.   
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INTRODUCTION 
 
Lymphangioleiomyiomatosis (LAM) is a rare progressive cystic lung disease that affects 
almost exclusively women [1]. LAM can occur sporadically, or can be associated with tuberous 
sclerosis complex (TSC); a rare disorder with multiorgan involvement effecting the brain, kidneys, 
heart, liver, skin and eyes and is associated with intellectual disability, epilepsy and autism spectrum 
disorder [2]. In either form, LAM results from mutations affecting the function of TSC1 or TSC2 
genes [3], encoding for hamartin and tuberin, respectively. Such proteins inhibit the mammalian 
target of the rapamycin (mTOR) signaling pathway, a major regulator of cell size and proliferation 
[4]. Moreover, TSC patients may develop multifocal micronodular pneumocyte hyperplasia 
(MMPH), a distinct micronodular epithelial proliferative lesion of the lung, with or without the 
coexistence of LAM [5]. MMPH is caused by the growth of proliferating epithelial cells into the 
alveolar walls which is not simply just pneumocyte hyperplasia [5]. Lung function abnormalities in 
LAM patients include the reduction of both forced expiratory volume in one second (FEV1) and lung 
diffusion for carbon monoxide (DLCO), which clinically corresponds to a reduction in breathing 
ability, and hypoxemia when performing physical activity and even at rest [6, 7]. 
A consensus statement issued by the European Respiratory Society in 2012 defined the 
diagnostic criteria for LAM [1]. In patients with definite or probable TSC, LAM can be diagnosed on 
the basis of a characteristic pulmonary high-resolution computed tomography (HRCT) pattern with 
the presence of more than 10 thin-walled, round and well-defined air-filled cysts with preserved or 
increased lung volume, and no other significant pulmonary involvement (with the exception of 
possible features of MMPH) present [1]. In the same document, HRCT scanning is recommended for 
women with TSC at ages between 18 and 30 years [1]. Previous studies run on women affected by 
TSC found a LAM prevalence ranging between 26 and 49% [8-13], with an increase of prevalence 
correlated to age that may reach 81% in subjects aged 40 years or older [10].  
 8 
 Sirolimus and its derivate everolimus are immunosuppressive drugs that affect mTOR 
function. Both have been demonstrated to be somewhat effective in the treatment of LAM [14-17]. 
With the advent of such therapies, early diagnosis of LAM has become crucial. However, since the 
prevalence of clinically significant LAM in TSC patients is low [18-22] and LAM-TSC is a milder 
disease compared to sporadic LAM [6, 22], the lifelong cumulative radiation exposure risk of serial 
CT should be taken into account. Cudzilo CJ et al. proposed an age-based approach using limited CT 
scanning methods in order to facilitate screening and limit radiation exposure [10].  
In our study, the evaluation of a possible association between pulmonary and extrapulmonary 
localization of TSC-related abnormalities was investigated with the objective to assess whether 
specific extrapulmonary manifestations typical of TSC, or other features of the disease may increase 
the risk of LAM. The aims were: 1) evaluation of the prevalence of LAM in a large TSC Italian 
population and usefulness of lung function tests for screening purposes; 2) assessment of the 
association between LAM-TSC and other features of the disease such as demographic characteristics 
of patients, the presence of extrapulmonary involvement and the identification of the mutation of 
gene TSC1 or TSC2; and 3) characterization of patients affected by MMPH alone. 
 
METHODS 
 
Study design and population 
This is a cohort retrospective study involving outpatients affected by TSC, regularly seen at 
the Tuberous Sclerosis Center of San Paolo Hospital, Milan, Italy, from 2000 to 2014. The diagnosis 
of TSC was established using international criteria [23]. In our TSC center every systemic 
manifestation of TSC is evaluated at least yearly by a specialist experienced in TSC diagnosis and 
management (neurologist, pulmonologist, nephrologist, dermatologist, ophthalmologist, radiologist, 
and cardiologist) according with international guidelines [23-26]. Pulmonary evaluation with high-
resolution lung CT (HRCT) was performed in women [1]: 1) at the age of 18 years for the patients 
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diagnosed with TSC in pediatric age; 2) at the moment of TSC diagnosis in adult patients or during 
the first evaluation in our center; 3) in case of respiratory symptoms. The analyzed data (demographic, 
clinical, genetic, pulmonary function tests, and extrapulmonary manifestations) refer to the year of 
chest CT.  
 
Pulmonary involvement 
Spirometry, body pletismography and lung diffusion tests (Platinum Elite™ MGC Diagnostic, 
USA) were performed according to ATS/ERS guidelines [27, 28]. We defined an alteration of 
pulmonary function test as 1) FEV1/FVC < lower level of normality, 2) reduction of lung diffusion 
for carbonic monoxide (DLCO) and/or 3) DLCO/alveolar volume (DLCO/VA) < 80% of predicted 
value using ECCS predicted values [29]. Dyspnea was investigated throughout the Italian version of 
the modified Medical Resource Council (MRC) scale consisting in five statements regarding 
perceived breathlessness [30]. The six-minute walk test (6MWT) was performed along a flat, straight, 
30 meters walking course supervised by a well-trained researcher according to ATS guidelines [31].  
 
Chest CT scans 
As previously described, in accordance with the ERS document, the presence of LAM in 
patients with definite or probable TSC was confirmed in the presence of characteristic lung high-
resolution CT patterns [1]. Chest CT examinations were performed without contrast media 
administration either on a 4-slice multidetector CT (Light Speed QX/i; General Electric Medical 
System, Milwaukee, WI) between January 2000 and August 2008 or, due to the scan system 
replacement, with a 64-slice multidetector CT (LightSpeed VCT, General Electric Healthcare, 
Milwaukee, WI) between September 2008 and December 2014. For both scanners, parameters 
comprised the following: tube voltage, 100-140 kVp; tube current, 120-400 mAs (with automatic 
tube current modulation for the 64-slice scanner); gantry rotation time, 0.5 s; reconstruction thickness, 
1.25 mm; reconstruction increment, 1.25 mm; acquisition kernel, standard. A beam pitch of 1.5 was 
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used for the 4-slice CT scanner and a pitch of 1 for the 64-slice one. Images were acquired during 
inspiration and the scan length extended from the lung apices to the adrenal glands. 
 
Genetic analysis 
Qiamp DNA blood mini DNA kit (Qiagen, Germany) was employed to extract DNA from 
peripheral lymphocytes (Qiagen, Germany). TSC1 and TSC2 exons from the genomic DNAs were 
amplified by means of standard polymerase chain reaction (PCR) and previously described primers 
[32]. Mutations were detected by submitting the PCR products to denaturing high-performance liquid 
chromatography (DHPLC) (Transgenomic, Crewe, UK). The products showing variant DHPLC melt 
profiles were directly sequenced using a BigDye terminator cycle sequencing kit (Applied 
Biosystems), and the results were analyzed using sequence analysis 3.4.1 software (ABI 3130, 
Applied Biosystem). The sequencing reactions for identified mutations were repeated. Patients that 
had negative investigations for DHPLC were evaluated with Multiple Ligation-dependent Probe 
Amplification test for TSC1 (P124-MRC-Holland) and TSC2 (P046-MRC-Holland). Patients in 
whom genetic analysis was inconclusive, were classified as having  no mutation identified (NMI). 
 
Neurological manifestations 
Neurological manifestations (cortical tubers, subependymal nodules (SEN) and 
subependymal giant cell astrocytoma (SEGA)) were evaluated by the use of CT and brain magnetic 
resonance imaging (MRI). Epilepsy and neurodevelopmental psychiatric/cognitive symptoms were 
also evaluated. Frequency, age at onset, and characteristics of epilepsy, intellectual disability, sleep 
disorders and anti-epileptic therapy were reported. Intellectual disability was divided into five grades 
according to intelligence quotient (IQ): (1) normal IQ with IQ > 85; (2) borderline intellectual 
functioning (BIF) with IQ from 84 to 71;(3) mild intellectual disability (ID) with IQ from 70 to 55;(4) 
moderate ID with IQ from 54 to 40, and (5) severe ID with IQ < 40 [33]. As part of their clinical 
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management, patients were evaluated through a psychiatric interview in order to assess possible Axis 
I and II disorders [33].  
 
Abdominal, dermatological and cardiac manifestations 
All patients were evaluated at least once with an abdomen CT or MRI [34], and followed-up 
with ultrasonography (US) in the majority of cases. Abdominal manifestations of TSC include renal 
angiomyolipomas, renal cysts and renal cell carcinoma and hepatic angiomyolipomas; the data 
included in our database refer to the closest CT or MRI available, obtained before or after the chest 
CT-scan. Skin lesions were also clinically evaluated. TSC manifestations include facial 
angiofibromas, forehead plaques, hypomelanotic macules, shagreen patches and ungual fibroma. 
Cardiac involvement (rhabdomyoma, electrocardiographic abnormalities) was investigated by 
electrocardiography and echocardiography.  
 
Statistics 
 The results are shown as meanstandard deviation (SD), unless otherwise stated. Lilliefors 
corrected K-S test was performed before the data analysis in order to examine the distribution of the 
residuals of the parametric tests. For comparisons between patients, unpaired Student’s t test analysis 
(test for equal variances was performed), Wilcoxon Mann-Whitney test, or Fisher’s exact test were 
used, as appropriate. Variables that resulted in p values < 0.15 were used in a multivariate logistic 
regression model to predict factors that were associated with TSC-LAM diagnosis. The odds ratios 
(OR) and their 95% confidence intervals were also derived. All tests were two-sided, and p < 0.05 
were considered statistically significant. Statistical tests were performed using the Statistical Package 
for Social Sciences (version 21.0; SPSS, Chicago, IL). 
 
Ethical considerations 
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The local ethical committee (Comitato Etico Interaziendale Milano Area A) approved the 
study. All patients recruited were required to give their signed consent for  the collection and analysis 
of clinical data. Patients with cognitive impairment had consent signed for them by appropriate next 
of kin. 
 
RESULTS 
 
Analysis of the Population and relationship between age and prevalence of LAM in TSC 
Among the 200 patients (80 males, 120 females; mean age 29 years, range 1-71) followed up 
for TSC at San Paolo Hospital (Milan, Italy) during the period of analysis, 142 were older than 18 
years of age (and therefore considered “adult patients”). Ninety-two adult women were evaluated; of 
them 86 (93%) had chest CT scans (Fig 1). Eighty-two of those scans (95%) were done for screening 
purposes (requested at the time of the first clinical evaluation); two patients underwent HRTC for 
pneumothorax, and two others for chylothorax (in these subjects the pulmonary involvement 
preceded the diagnosis of TSC) during hospitalization. Chest CT scan allowed the following 
identifications: 66 (77%) adult women had pulmonary involvement with LAM in 42 cases (49%), 
MMPH in 24 cases (28%), and both LAM and MMPH in 19 cases (22%). 
Demographic and clinical features of the population are shown in Table 1. The mean age at 
first CT evaluation was significantly higher (> 9 years difference) for patients with LAM compared 
to those without LAM (p< 0.001). LAM prevalence significantly increased across age quartiles 
(p=0.005) in the overall population (Fig 2A); TSC2 mutation was found in 50% of the cases. Such 
percentage changed when the presence of LAM was considered, with a statistically borderline higher 
prevalence of TSC2 mutation in LAM patients (60 vs. 38%, p=0.070). In the overall population, the 
most common mutation was “de novo” (61%), with the same number of “familial” and “dubious” 
mutations; in terms of mutations, no significant differences were found in patients with and without 
LAM (p=0.282). 
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Pulmonary involvement, symptoms and respiratory function 
Respiratory function tests were successfully carried out in 55 patients (64%), due to the high 
prevalence of intellectual disability and/or behavioral problems (Table 2); namely, 14 patients were 
not co-operative, in 7 cases spirometry was not acceptable due to glottis closure, 5 had variable effort 
with early termination of forced expiration and 5 patients were not able to perform reproducible tests. 
LAM patients showed lower DLCO and DLCO/VA (both referred to predicted values); the difference 
in terms of obstruction (i.e. FEV1/FVC ratio under lower limit of normality, LLN) between LAM 
and TSC-LAM resulted in borderline statistical significance (p=0.080). Impairment in lung function 
tests is more common in TSC-LAM patients than in TSC patients without LAM (p=0.055). As shown 
in Fig 2B, patients with an altered lung function showed a higher percentage of LAM with age. Five 
TSC-LAM patients had a history of recurrent pneumothorax. Patients with or without LAM did not 
differ in dyspnoea and oxygen desaturation during 6MWT. We also evaluated the usefulness of 
pulmonary function tests in the subgroup of 16 women with “respiratory impairment” (i.e. dyspnoea, 
pneumothorax, or chylothorax). The prevalence of LAM in this subgroup did not differ significantly 
from asymptomatic patients (26 vs. 11%, p=0.068), such as the results of pulmonary function tests, 
with the only exception of a borderline reduction of DLCO (i.e. <80%) in patients with symptoms 
(38 vs. 14%, p=0.050). 
 
Extrathoracic involvement and MMPH patients 
Renal (multiple and bilateral), and hepatic angiomyolipomas were significantly more frequent 
in patients with LAM, compared to those without LAM (p=0.011, and p=0.002, respectively). In 
addition, women with LAM less frequently had a history of epilepsy than patients without LAM 
(p=0.076) (Table 1).  
Twenty-five patients with MMPH alone (i.e. without LAM) have been compared with 24 patients 
with no pulmonary involvement. Patients having MMPH alone did not differ from the other TSC 
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patients without any lung manifestation in terms of clinical features, neuropsychiatric symptoms, 
genetic characteristics, and lung function tests (Table 3). 
 
Predictors of TSC-LAM 
Pulmonary function test alterations alone yielded a sensitivity of 45% and specificity of 70% 
for LAM diagnosis by using CT scan as gold standard, with a positive and negative predicted value 
of 59% and 57% respectively. A multivariate model was used to estimate the odds for LAM diagnosis. 
The only element found in the univariate analysis that was independently associated with LAM 
diagnosis in our TSC group was the age at first CT evaluation, with a higher risk of LAM in older 
women (Table 4). Our analysis failed to demonstrate alterations of PFT as independently associated 
with LAM in TSC patients (p=0.245).  
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DISCUSSION 
The main findings of this study, conducted on a large cohort of Italian TSC patients, are the 
following: 1) LAM and MMPH have a prevalence of 49% and 28% respectively; 2) on average, 
women with LAM are older, develop renal and hepatic angiomyolipomas more frequently, show a 
higher rate of pneumothoraces, and have more mutations on the TSC2 gene; 3) Impairment in lung 
function tests, feasible in patients not affected by major cognitive deficit (64%), is more common in 
LAM patients; 4) older age is independently associated with LAM whereas multivariate analysis 
failed to demonstrate pulmonary function test alterations as an independent risk factor for LAM 
diagnosis; 5) patients with MMPH alone do not show a specific clinical, functional or genetic profile.  
To the best of our knowledge, this is the first study that describes the clinical characteristics 
of a large Italian population of  patients with LAM associated with TSC and that investigates the 
possible role of respiratory function test in detecting pulmonary involvement.  
Our data, in line with previous studies [8-13], indicate that in TSC patients there is an age-
related LAM prevalence, a higher frequency of TSC2 mutations (statistically borderline in our study) 
[11, 35, 36], and more frequent occurrence of renal [10, 11, 22] and hepatic angiomyolipomas [37]. 
The crucial importance of “time” in the manifestation of lung lesions is probably due to the 
pathogenesis of LAM-TSC, which is consistent with the Knudson “two-hit” tumor suppressor gene 
mechanism [38]. Moreover, in line with previous data, our results support the evidence that patients 
with TSC1 mutations have, on average, milder disease in comparison with patients with TSC2 
mutations [13, 39].  
We encountered two major difficulties in the use of pulmonary function tests in TSC patients: 
firstly, 36% of TSC women who underwent chest CT failed to correctly perform spirometry and other 
pulmonary function tests due to TSC-related intellectual disability. This could potentially be aided 
by the use of other techniques that require a lower level of co-operation, such as using forced 
oscillation technique (FOT), a simple, noninvasive method which requires minimal patient technical 
ability, currently used in both children and adults. The second problem was the low sensitivity (<50%) 
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of PFTs for LAM screening in TSC women. This may be due to numerous issues, e.g. TSC patients 
usually present with a mild form of LAM, LAM is the initial presenting symptom of TSC only 
occasionally, and the decline in lung function is typically very gradual in patients with LAM-TSC, 
with only a minority of patients becoming symptomatic during follow-up [40-42]. However, an 
interesting study conducted by Taveira-DaSilva AM et al. showed that some young LAM-TSC 
patients (mean age 26±3 years) can rapidly progress from minimal to severe lung disease [22]. The 
real question is whether it is important to diagnose LAM in asymptomatic patients, which on average 
present with very mild lung disease. Screening for LAM in TSC patients should take into 
consideration potential benefits and risks. Potential benefits of earlier LAM diagnosis include the 
possibility to inform women about the risk of a pneumothorax, pregnancy, the use of contraceptives, 
and lifestyle choices, such as scuba diving or smoking, as well as the opportunity to start mTOR 
inhibitor therapy, even if this choice is currently limited to patients with lung function declining 
rapidly or respiratory symptoms, chylous pleural effusion or ascites [43]. On the other hand, the risk 
of carcinogenic ionizing radiation exposure has to be taken into account, as well as the possible 
anxiety due the diagnosis, and lifestyle limitations (e.g. the risk of pneumothorax and air travel) not 
supported by a strong level of evidence (e.g. the risk of a life-threatening pneumothorax associated 
with air travel is minor) [44]. 
Our study confirms that, so far, HRCT is the only available tool for LAM screening in TSC 
patients. Multivariate analysis failed to identify a parameter that is independently associated with the 
presence of LAM, with the only exception of age. To conclude, the need of LAM diagnosis by chest 
HRCT scan in asymptomatic TSC women with normal lung function should be weighed in each 
individual circumstance with consideration of the pros and cons. 
The significant percentage of TSC patients showing MMPH (50%) correlates halfway 
between previous reports [11] and a recent work by Muzykewicz et al. [45] that found a nodular 
lesion prevalence of 57% in TSC patients. We did not find a significant correlation between the 
presence of MMPH and LAM since the rate of MMPH was the same in patients with and without 
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LAM (p=0.518). Moreover, even if not confirmed by statistically significant results, MMPH alone 
seems to be more common in older patients (5 years of difference compared to TSC patients without 
any lung involvement, p=0.074). However, the presence of MMPH itself does not affect pulmonary 
function, with pulmonary function tests on average normal in those patients and comparable with 
TSC women without evidence of lung disease. Thus, the evidence of MMPH at HRCT should be 
considered as clinically negligible, with the exception, in our experience, of occasional atypical 
radiological findings which require follow-up in order to exclude other diagnosis (e.g. in situ 
adenocarcinoma).  
A number of potential limits of the present study deserve discussion. First, due to the 
retrospective nature of our work, we did not determine any biomarker, such as vascular endothelial 
growth factor-D (VEGF-D) at time of first HRTC, which demonstrated a potential clinical utility in 
reaching a diagnosis of LAM [46]. The correlation between higher values of VEGF-D and a reduced 
lung function has been found in some but not all studies [46-50]. However, no study has specifically 
investigated the potential role of the combination of pulmonary function tests and biomarkers for the 
diagnosis of LAM, reason why this approach is worth of investigation. Secondly, the understanding 
of TSC and LAM has significantly changed in the period of our data collection. Even if this is not a 
limit for pulmonary function tests, since spirometry and DLCO are unchanged for decades, we cannot 
rule out a possible bias for changes in the evaluation of extrapulmonary manifestation of the disease 
in the 14 years of data collection. Third, as suggested by many international documents, CT-scan 
evaluation was limited to women, since the presence of cysts in men is anecdotal. The reason being 
we cannot rule out some LAM-like lesions that are present in men with TSC, as previously reported 
[51]. We also did not analyze the data of abdominal lymphangioleiomyomas or of lymphadenopathy 
since scarcity in the number of patients. Finally the, power of our multivariate analysis is low, due to 
the limited number of patients with all the parameters available for analysis. 
CONCLUSIONS 
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Impairment in lung function tests is common in LAM, but pulmonary function testing, needed 
to evaluate the level of lung impairment, does not prove to be a useful tool for detecting LAM in TSC 
women in clinical practice. Using more sensitive tests which require a lower level of co-operation 
could assist, if available. However, the weak correlation between lung function impairment, 
"anatomical" lung cysts and symptoms limits the utility of lung function testing for LAM in patients 
with TSC. The use of low dose CT methods are suggested to limit the lifelong cumulative radiation 
exposure.   
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FIGURES 
 
FIGURE 1.  
Population in analysis. Age is shown as mean ± standard deviation and is referred to first evaluation 
in the center. LAM=lymphangioleiomyomatosis; TSC= tuberous sclerosis complex; *percentage 
referred to all adult TSC females patients in which lung scan was available for evaluation. 
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FIGURE 2. 
AGE -DEPENDENT RISK OF LAM. (A) on age quartiles in the overall population (p=0.004) (B) 
predicted probability of LAM in relationship to age and 95% CI in patients with and without altered 
pulmonary function tests. Points along the central logistic curve are individual predicted probabilities. 
Black points refer to patients with normal pulmonary function tests (PFT), white points refer to 
patients with altered PFT. The corresponding 95% CI for each point appears on the outer logistic 
curves. The dotted lines refer to 95% CI of predicted probability for patients with altered PFT while 
the continuous line refers to IC in patients with normal PFT 
 
 
.  
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TABLES 
 
Table 1. Demographic and clinical characteristics of enrolled patients according with LAM.  
 
 
ALL 
PATIENTS 
LAM-TSC TSC 
P 
value 
Number (%) 86 42 (49) 44 (51)  
Age at first CT evaluation, yrs 34 ± 12 39 ± 12 30 ± 9 <0.001 
Genotypea     
TSC1, n (%) 33 (40) 11 (28) 22 (52) 
0.070 TSC2, n (%) 40 (49) 24 (60) 16 (38) 
No mutation identified (NMI), n (%) 9 (11) 5 (12) 4 (10) 
Abdominal manifestation 
Renal angiomyolipomas, n (%) 63 (75) 36 (88) 27 (62) 0.011 
n <3/n≥ 3, n (%) 9 (25)/ 27 (75) 3 (11)/ 23 (89) 6 (60)/ 4 (40) 0.006 
bilateral angiomyolipomas, n (%) 32 (80) 23 (88) 9 (64) 0.102 
Renal cysts, n (%) 30 (40) 16 (44) 14 (37) 0.636 
Hepatic angiomyolipoma, n (%) 29 (35) 22 (54) 7 (17) 0.002 
Skin lesions, n (%) 84 (99) 41 (100) 43 (97) >0.999 
Hypomelanotic macules, n (%) 51 (91) 26 (93) 25 (89) >0.999 
Facial angiofibromas, n (%) 58 (97) 30 (100) 28 (90) 0.492 
Fiorhead plaque, n (%) 26 (81) 10 (77) 16 (84) 0.666 
Shagreen patches, n (%) 13 (41) 7 (50) 6 (33) 0.473 
Ungual fibromas, n (%) 30 (77) 18 (95) 12 (60) 0.020 
Neurological manifestation 
Epilepsy, n (%) 54 (64) 22 (54) 32 (72) 0.076 
Cortical tubers, n (%) 78 (92) 37 (88) 41 (95) 0.265 
Subependymal nodules, n (%) 58 (76) 29 (78) 29 (74) 0.790 
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SEGA, n (%) 13 (17) 8 (22) 5 (13) 0.591 
Sleep disorders, n (%) 58 (89) 26 (87) 32 (91) 0.695 
Intellectual disability, n (%) 35 (44) 19 (47) 16 (40) 0.652 
Borderline, n (%) 5 (6) 4 (10) 1 (2) 
0.586 
Level 1, n (%) 10 (12) 5 (12) 5 (12) 
Level 2, n (%) 8 (10) 3 (7) 5 (12) 
Level 3, n (%) 12 (15) 7 (17) 5 (12) 
Ocular manifestation 
Fundus oculi abnormalities, n (%) 32 (73) 15 (68) 17 (77) 0.736 
Retinic amartomas, n (%) 6 (46) 2 (29) 4 (67) 0.286 
Cardiac manifestation 
Cardiac rhabdomyomas, n (%) 12 (17) 4 (11) 8 (22) 0.343 
Results are shown as mean standard deviation unless otherwise stated. SEGA: subependymal giant cell astrocytoma; 
IQR: interquartile range; SD: standard deviation. p < 0.050 in bold. aResults of genetic analysis were available for 82 
TSC patients. 
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Table 2. Lung function, pulmonary manifestations and symptoms of patients according with 
LAM.  
 
 
ALL 
PATIENTS 
LAM-TSC TSC 
P 
value 
Lung functiona 
FEV1 (% pred), median (IQR)  95 (85-106) 95 (85-106) 94 (86-108) 0.736 
FVC (% pred) 99 ± 17 100 ± 19 97 ± 15 0.607 
FEV1/FVC ratio, median (IQR) 101 (96-104) 99 (94-103) 102 (97-104) 0.166 
FEV1/FVC ratio < LLN, n (%) 6 (11) 5 (21) 1 (3) 0.080 
DLCO (% pred) 81 ± 18 74 ± 22 86 ± 14 0.029 
VA (% pred) 96 ± 15 93 ±16 98 ± 14 0.229 
DLCO/VA (% pred) 81 ± 18 74 ± 20 87 ± 15 0.007 
DLCO/VA < 80% pred, n (%) 25 (46) 16 (64) 9 (31) 0.028 
VR (% pred) 131 ±  59 140 ± 65 127 ± 56 0.502 
TGV (% pred) 116 ±34 123 ± 38 112 ± 31 0.358 
Alteration of PFT, n (%) 32 (58) 19 (73) 13 (44) 0.055 
Lung involvementb 
Smoke history (current/ex), n (%) 8 (9)/ 1 (1) 6 (14)/ 1 (3) 2 (4)/ 0 (0) 0.166 
Pneumothorax, n (%) 5 (6) 5 (12) 0 (0) 0.024 
Chylothorax 3 (3) 3 (7) 0 (0) 0.112 
MMPH, n (%) 43 (50) 19 (45) 24 (55) 0.518 
Dyspnea, n (%) 14 (17) 9 (23) 5 (11) 0.241 
     mMRC =1, n (%) 2 (14) 1 (11) 1 (20) 
0.486 
 mMRC >1, n (%) 12 (86) 8 (89) 4 (80) 
SpO2 < 90% during 6mWT, n (%) 11 (14) 4 (10) 7 (18) 0.518 
Results are shown as mean standard deviation  unless otherwise stated. PFT: pulmonary function test (alteration: 
FEV1/FVC < LLN, and/or DLCO < 80%, and/or DLCO/VA < 80%); IQR: interquartile range; FEV1: forced expiratory 
volume in one second; FVC: forced expiratory volume; LLN: lower limit of normality; DLCO: diffusion capacity for CO; 
VA: alveolar volume; TLC: total lung capacity; RV: residual volume; TGV: thoracic gas volume; MMPH: multifocal 
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micronodular pneumocyte hyperplasia; mMRC: Modified Medical Research Council Dyspnea Scale, %pred: % of 
predicted value; p < 0.050 in bold. aData and percentage referred to 55 patients who performed lung function tests; 
bData and percentage referred to 86 patients with CT scan. 
 
 
Table 3. Demographic, pulmonary, clinical characteristic and genetic analysis of TSC patients 
according with MMPH. 
 
 MMPH-TSC TSC 
P 
value 
Number 24 20  
Age at first CT evaluation, (yrs) 32 ± 7 27 ± 10 0.074 
Dyspnea, n (%) 4 (83) 4 (17) 0.362 
Smoke history (current or past), n (%) 1 (4) 1 (5) >0.999 
SO2 < 90% during 6mWT, n (%) 6 (29) 1 (5) 0.095 
Respiratory function 
FEV1 (% pred) 96 ± 13 98 ± 8 0.550 
FEV1/FVC < LLN, n (%) 1 (5) 0 (0) >0.999 
FVC (% pred) 98 ± 16 97 ±13 0.806 
DLCO (% pred) 84 ± 13 90 ±15 0.297 
VA (% pred) 100 ±15 96 ±14 0.562 
DLCO/VA (% pred) 86 ±13 89 ± 17 0.697 
RV (% pred) 125 ±63 128 ±31 0.881 
Genotype 
TSC1, n (%) 14 (58) 8 (44) 
0.355 TSC2, n (%) 9 (37) 7 (39) 
No mutation identified (NMI), n (%) 1 (4) 3 (17) 
Abdominal manifestations 
Renal angiomyolipomas, n (%) 12 (50) 15 (79) 0.064 
Hepatic angiomyolipoma, n (%) 3 (14) 4 (21) 0.760 
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Skin involvementa, n (%) 24 (100) 19 (95) 0.455 
Neurological manifestations    
Epilepsy, n (%) 18 (75) 14 (70) 0.746 
Brain tubers, n (%) 23 (100) 18 (90) 0.210 
Intellectual disability, n (%) 7 (33) 9 (47) 0.520 
Ocular manifestations 
Retinic hamartoma, n (%) 4 (100) 0 (0) 0.067 
Cardiac hamartoma, n (%) 3 (15) 5 (31) 0.422 
Results are shown as mean standard deviation unless otherwise stated. IQR: interquartile range; 
FEV1: forced expiratory volume in one second; FVC: forced expiratory volume; LLN: lower limit 
of normality; DLCO: diffusion capacity for CO; VA: alveolar volume; TLC: total lung capacity; 
RV: residual volume; TGV: thoracic gas volume; yrs: years; %pred: % of predicted value. aAny 
skin manifestation of TSC. 
 
 
 
 
 
Table 4. Multivariate Analysis and ODDS RATIO for LAM risk in overall population.  
 UNIVARIATE MULTIVARIATE 
Variable OR 95% CI p value OR 95% CI p value 
Haepatic AML 4.26 1.39-13.09 0.011 - - - 
Renal AML 2.26 1.02-5.00 0.430 - - - 
Altered PFT 3.34 1.07-10.38 0.037 - - - 
TSC1/TSC2 1.52 0.79-2.95 0.207 - - - 
Age 1.08 1.03-1.13 0.001 1.083 1.014-1.156 0.018 
AML: angiomyolipoma; PFT: pulmonary function test; TSC1/2/NMI: mutation of TSC1 TSC2 
genes/ no mutation identified; Age: referred to age at first CT evaluation;  p < 0.050 in bold. 
  
 26 
REFERENCES 
 
1. Johnson SR, Cordier JF, Lazor R, Cottin V, Costabel U, Harari S, et al. European Respiratory 
Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. Eur 
Respir J. 2010;35(1):14-26. doi: 10.1183/09031936.00076209. PubMed PMID: 20044458. 
2. Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet. 2008;372(9639):657-68. 
doi: 10.1016/S0140-6736(08)61279-9. PubMed PMID: 18722871. 
3. Yu J, Astrinidis A, Henske EP. Chromosome 16 loss of heterozygosity in tuberous sclerosis 
and sporadic lymphangiomyomatosis. Am J Respir Crit Care Med. 2001;164(8 Pt 1):1537-40. 
doi: 10.1164/ajrccm.164.8.2104095. PubMed PMID: 11704609. 
4. Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes 
and ageing. Nat Rev Mol Cell Biol. 2011;12(1):21-35. doi: 10.1038/nrm3025. PubMed PMID: 
21157483; PubMed Central PMCID: PMC3390257. 
5. Maruyama H, Ohbayashi C, Hino O, Tsutsumi M, Konishi Y. Pathogenesis of multifocal 
micronodular pneumocyte hyperplasia and lymphangioleiomyomatosis in tuberous sclerosis 
and association with tuberous sclerosis genes TSC1 and TSC2. Pathol Int. 2001;51(8):585-94. 
PubMed PMID: 11564212. 
6. Ryu JH, Moss J, Beck GJ, Lee JC, Brown KK, Chapman JT, et al. The NHLBI 
lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment. Am J Respir 
Crit Care Med. 2006;173(1):105-11. doi: 10.1164/rccm.200409-1298OC. PubMed PMID: 
16210669; PubMed Central PMCID: PMC2662978. 
7. Taveira-DaSilva AM, Pacheco-Rodriguez G, Moss J. The natural history of 
lymphangioleiomyomatosis: markers of severity, rate of progression and prognosis. Lymphatic 
research and biology. 2010;8(1):9-19. doi: 10.1089/lrb.2009.0024. PubMed PMID: 20235883; 
PubMed Central PMCID: PMC2883494. 
8. Adriaensen ME, Schaefer-Prokop CM, Duyndam DA, Zonnenberg BA, Prokop M. 
Radiological evidence of lymphangioleiomyomatosis in female and male patients with tuberous 
sclerosis complex. Clin Radiol. 2011;66(7):625-8. doi: 10.1016/j.crad.2011.02.009. PubMed 
PMID: 21459371. 
9. Costello LC, Hartman TE, Ryu JH. High frequency of pulmonary lymphangioleiomyomatosis 
in women with tuberous sclerosis complex. Mayo Clin Proc. 2000;75(6):591-4. doi: 
10.4065/75.6.591. PubMed PMID: 10852420. 
 27 
10. Cudzilo CJ, Szczesniak RD, Brody AS, Rattan MS, Krueger DA, Bissler JJ, et al. 
Lymphangioleiomyomatosis screening in women with tuberous sclerosis. Chest. 
2013;144(2):578-85. doi: 10.1378/chest.12-2813. PubMed PMID: 23539171. 
11. Franz DN, Brody A, Meyer C, Leonard J, Chuck G, Dabora S, et al. Mutational and 
radiographic analysis of pulmonary disease consistent with lymphangioleiomyomatosis and 
micronodular pneumocyte hyperplasia in women with tuberous sclerosis. Am J Respir Crit Care 
Med. 2001;164(4):661-8. doi: 10.1164/ajrccm.164.4.2011025. PubMed PMID: 11520734. 
12. Moss J, Avila NA, Barnes PM, Litzenberger RA, Bechtle J, Brooks PG, et al. Prevalence and 
clinical characteristics of lymphangioleiomyomatosis (LAM) in patients with tuberous sclerosis 
complex. Am J Respir Crit Care Med. 2001;164(4):669-71. doi: 
10.1164/ajrccm.164.4.2101154. PubMed PMID: 11520735. 
13. Muzykewicz DA, Sharma A, Muse V, Numis AL, Rajagopal J, Thiele EA. TSC1 and TSC2 
mutations in patients with lymphangioleiomyomatosis and tuberous sclerosis complex. J Med 
Genet. 2009;46(7):465-8. doi: 10.1136/jmg.2008.065342. PubMed PMID: 19419980. 
14. Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, et al. Sirolimus for 
angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med. 
2008;358(2):140-51. doi: 10.1056/NEJMoa063564. PubMed PMID: 18184959; PubMed 
Central PMCID: PMC3398441. 
15. McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, et al. Efficacy and safety 
of sirolimus in lymphangioleiomyomatosis. N Engl J Med. 2011;364(17):1595-606. doi: 
10.1056/NEJMoa1100391. PubMed PMID: 21410393; PubMed Central PMCID: 
PMC3118601. 
16. Taveira-DaSilva AM, Hathaway O, Stylianou M, Moss J. Changes in lung function and chylous 
effusions in patients with lymphangioleiomyomatosis treated with sirolimus. Ann Intern Med. 
2011;154(12):797-805, W-292-3. doi: 10.7326/0003-4819-154-12-201106210-00007. 
PubMed PMID: 21690594; PubMed Central PMCID: PMC3176735. 
17. Goldberg HJ, Harari S, Cottin V, Rosas IO, Peters E, Biswal S, et al. Everolimus for the 
treatment of lymphangioleiomyomatosis: a phase II study. Eur Respir J. 2015. doi: 
10.1183/09031936.00210714. PubMed PMID: 26113676. 
18. Tuberous sclerosis and the lungs. Br Med J. 1971;3(5766):64. PubMed PMID: 5090819; 
PubMed Central PMCID: PMC1800147. 
19. Castro M, Shepherd CW, Gomez MR, Lie JT, Ryu JH. Pulmonary tuberous sclerosis. Chest. 
1995;107(1):189-95. PubMed PMID: 7813275. 
 28 
20. Corrin B, Liebow AA, Friedman PJ. Pulmonary lymphangiomyomatosis. A review. Am J 
Pathol. 1975;79(2):348-82. PubMed PMID: 1146965; PubMed Central PMCID: PMC1912658. 
21. Shepherd CW, Gomez MR, Lie JT, Crowson CS. Causes of death in patients with tuberous 
sclerosis. Mayo Clin Proc. 1991;66(8):792-6. PubMed PMID: 1861550. 
22. Taveira-DaSilva AM, Jones AM, Julien-Williams P, Yao J, Stylianou M, Moss J. Severity and 
outcome of cystic lung disease in women with tuberous sclerosis complex. Eur Respir J. 
2015;45(1):171-80. doi: 10.1183/09031936.00088314. PubMed PMID: 25537563. 
23. Roach ES, Gomez MR, Northrup H. Tuberous sclerosis complex consensus conference: revised 
clinical diagnostic criteria. Journal of child neurology. 1998;13(12):624-8. PubMed PMID: 
9881533. 
24. Krueger DA, Northrup H, International Tuberous Sclerosis Complex Consensus G. Tuberous 
sclerosis complex surveillance and management: recommendations of the 2012 International 
Tuberous Sclerosis Complex Consensus Conference. Pediatric neurology. 2013;49(4):255-65. 
doi: 10.1016/j.pediatrneurol.2013.08.002. PubMed PMID: 24053983; PubMed Central 
PMCID: PMC4058297. 
25. Northrup H, Krueger DA, International Tuberous Sclerosis Complex Consensus G. Tuberous 
sclerosis complex diagnostic criteria update: recommendations of the 2012 Iinternational 
Tuberous Sclerosis Complex Consensus Conference. Pediatric neurology. 2013;49(4):243-54. 
doi: 10.1016/j.pediatrneurol.2013.08.001. PubMed PMID: 24053982; PubMed Central 
PMCID: PMC4080684. 
26. Roach ES, Sparagana SP. Diagnosis of tuberous sclerosis complex. Journal of child neurology. 
2004;19(9):643-9. PubMed PMID: 15563009. 
27. Macintyre N, Crapo RO, Viegi G, Johnson DC, van der Grinten CP, Brusasco V, et al. 
Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur 
Respir J. 2005;26(4):720-35. doi: 10.1183/09031936.05.00034905. PubMed PMID: 16204605. 
28. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative 
strategies for lung function tests. Eur Respir J. 2005;26(5):948-68. doi: 
10.1183/09031936.05.00035205. PubMed PMID: 16264058. 
29. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and 
forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, 
European Community for Steel and Coal. Official Statement of the European Respiratory 
Society. The European respiratory journal Supplement. 1993;16:5-40. PubMed PMID: 
8499054. 
 29 
30. Mahler DA, Wells CK. Evaluation of clinical methods for rating dyspnea. Chest. 
1988;93(3):580-6. PubMed PMID: 3342669. 
31. Laboratories ATSCoPSfCPF. ATS statement: guidelines for the six-minute walk test. Am J 
Respir Crit Care Med. 2002;166(1):111-7. doi: 10.1164/ajrccm.166.1.at1102. PubMed PMID: 
12091180. 
32. Jones AC, Sampson JR, Hoogendoorn B, Cohen D, Cheadle JP. Application and evaluation of 
denaturing HPLC for molecular genetic analysis in tuberous sclerosis. Human genetics. 
2000;106(6):663-8. PubMed PMID: 10942116. 
33. Association. AP. Diagnostic and statistical manual of mental disorders (4th ed., text rev.) 
American Psychiatric Association, Washington, D.C. 2000. 
34. Flum AS, Hamoui N, Said MA, Yang XJ, Casalino DD, McGuire BB, et al. Update on the 
Diagnosis and Management of Renal Angiomyolipoma. The Journal of urology. 2015. doi: 
10.1016/j.juro.2015.07.126. PubMed PMID: 26612197. 
35. Sato T, Seyama K, Fujii H, Maruyama H, Setoguchi Y, Iwakami S, et al. Mutation analysis of 
the TSC1 and TSC2 genes in Japanese patients with pulmonary lymphangioleiomyomatosis. 
Journal of human genetics. 2002;47(1):20-8. doi: 10.1007/s10038-002-8651-8. PubMed PMID: 
11829138. 
36. Strizheva GD, Carsillo T, Kruger WD, Sullivan EJ, Ryu JH, Henske EP. The spectrum of 
mutations in TSC1 and TSC2 in women with tuberous sclerosis and lymphangiomyomatosis. 
Am J Respir Crit Care Med. 2001;163(1):253-8. doi: 10.1164/ajrccm.163.1.2005004. PubMed 
PMID: 11208653. 
37. Tobino K, Johkoh T, Fujimoto K, Sakai F, Arakawa H, Kurihara M, et al. Computed 
tomographic features of lymphangioleiomyomatosis: evaluation in 138 patients. Eur J Radiol. 
2015;84(3):534-41. doi: 10.1016/j.ejrad.2014.12.008. PubMed PMID: 25544557. 
38. Henske EP, McCormack FX. Lymphangioleiomyomatosis - a wolf in sheep's clothing. The 
Journal of clinical investigation. 2012;122(11):3807-16. doi: 10.1172/JCI58709. PubMed 
PMID: 23114603; PubMed Central PMCID: PMC3484429. 
39. Dabora SL, Jozwiak S, Franz DN, Roberts PS, Nieto A, Chung J, et al. Mutational analysis in 
a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with 
TSC1, disease in multiple organs. Am J Hum Genet. 2001;68(1):64-80. doi: 10.1086/316951. 
PubMed PMID: 11112665; PubMed Central PMCID: PMC1234935. 
40. Franz DN, Bissler JJ, McCormack FX. Tuberous sclerosis complex: neurological, renal and 
pulmonary manifestations. Neuropediatrics. 2010;41(5):199-208. doi: 10.1055/s-0030-
1269906. PubMed PMID: 21210335. 
 30 
41. McCormack FX. Lymphangioleiomyomatosis: a clinical update. Chest. 2008;133(2):507-16. 
doi: 10.1378/chest.07-0898. PubMed PMID: 18252917. 
42. Seibert D, Hong CH, Takeuchi F, Olsen C, Hathaway O, Moss J, et al. Recognition of tuberous 
sclerosis in adult women: delayed presentation with life-threatening consequences. Ann Intern 
Med. 2011;154(12):806-13, W-294. doi: 10.7326/0003-4819-154-12-201106210-00008. 
PubMed PMID: 21690595; PubMed Central PMCID: PMC3367307. 
43. Taveira-DaSilva AM, Moss J. Management of lymphangioleiomyomatosis. F1000Prime Rep. 
2014;6:116. doi: 10.12703/P6-116. PubMed PMID: 25580270; PubMed Central PMCID: 
PMC4251421. 
44. Taveira-DaSilva AM, Burstein D, Hathaway OM, Fontana JR, Gochuico BR, Avila NA, et al. 
Pneumothorax after air travel in lymphangioleiomyomatosis, idiopathic pulmonary fibrosis, 
and sarcoidosis. Chest. 2009;136(3):665-70. doi: 10.1378/chest.08-3034. PubMed PMID: 
19318672; PubMed Central PMCID: PMC2775992. 
45. Muzykewicz DA, Black ME, Muse V, Numis AL, Rajagopal J, Thiele EA, et al. Multifocal 
micronodular pneumocyte hyperplasia: computed tomographic appearance and follow-up in 
tuberous sclerosis complex. J Comput Assist Tomogr. 2012;36(5):518-22. doi: 
10.1097/RCT.0b013e318264e404. PubMed PMID: 22992599. 
46. Chang WY, Cane JL, Blakey JD, Kumaran M, Pointon KS, Johnson SR. Clinical utility of 
diagnostic guidelines and putative biomarkers in lymphangioleiomyomatosis. Respiratory 
research. 2012;13:34. doi: 10.1186/1465-9921-13-34. PubMed PMID: 22513045; PubMed 
Central PMCID: PMC3431996. 
47. Glasgow CG, Avila NA, Lin JP, Stylianou MP, Moss J. Serum vascular endothelial growth 
factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement. 
Chest. 2009;135(5):1293-300. doi: 10.1378/chest.08-1160. PubMed PMID: 19420197; 
PubMed Central PMCID: PMC2818417. 
48. Seyama K, Kumasaka T, Souma S, Sato T, Kurihara M, Mitani K, et al. Vascular endothelial 
growth factor-D is increased in serum of patients with lymphangioleiomyomatosis. Lymphatic 
research and biology. 2006;4(3):143-52. doi: 10.1089/lrb.2006.4.143. PubMed PMID: 
17034294. 
49. Xu KF, Zhang P, Tian X, Ma A, Li X, Zhou J, et al. The role of vascular endothelial growth 
factor-D in diagnosis of lymphangioleiomyomatosis (LAM). Respiratory medicine. 
2013;107(2):263-8. doi: 10.1016/j.rmed.2012.10.006. PubMed PMID: 23127572. 
50. Young L, Lee HS, Inoue Y, Moss J, Singer LG, Strange C, et al. Serum VEGF-D a 
concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a 
 31 
prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of 
Sirolimus (MILES) trial. The Lancet Respiratory medicine. 2013;1(6):445-52. doi: 
10.1016/S2213-2600(13)70090-0. PubMed PMID: 24159565; PubMed Central PMCID: 
PMC3804556. 
51. Ryu JH, Sykes AM, Lee AS, Burger CD. Cystic lung disease is not uncommon in men with 
tuberous sclerosis complex. Respiratory medicine. 2012;106(11):1586-90. doi: 
10.1016/j.rmed.2012.07.007. PubMed PMID: 22871462. 
 
  
 32 
CHAPTER II: LYMPHANGIOLEIOMYOMATOSIS, MULTIFOCAL MICRONODULAR 
PNEUMOCYTE HYPERPLASIA, AND SARCOIDOSIS: MORE PATHOLOGICAL FINDINGS 
IN THE SAME CHEST CT, OR A SINGLE PATHOLOGICAL PATHWAY? 
 
ABSTRACT 
 
Autoimmune hepatitis/primary biliary cirrhosis overlap syndrome, 
lymphangioleiomyomatosis/tuberous sclerosis complex (LAM-TSC), and sarcoidosis are three rare 
diseases. Here we present, to the best of our knowledge, the first description of a patient with the 
coexistence of these three diseases. 
A 47-year-old woman affected by LAM-TSC and primary biliary cirrosis/autoimmune 
hepatitis overlap syndrome. During her follow up a high resolution chest CT scan (HRTC) confirmed 
the presence of both multiple cysts and micronodular opacities consistent with multifocal 
micronodular pneumocytes hyperlasia (MMPH), and revealed multiple hilar-mediastinal symmetrical 
lymphadenopathies suggestive of sarcoidosis. Simultaneously, subcutaneous nodules appeared on her 
forearm bilaterally. Cutaneous biopsy showed granulomatous dermatitis with sarcoid-like 
granulomas. A diagnosis of stage I pulmonary sarcoidosis was made. No treatment for sarcoidosis 
was initiated since the patient had neither systemic involvement, nor respiratory impairment.  
The presence of more than one rare disease should challenge the concept of a potential 
common underlying mechanism, since the a priori probability of the concomitant presence of 
different conditions with different pathogenic mechanisms - especially if rare diseases - is low.  
We speculate that the dysregulation of the pathway involving mTOR and MAPK and their 
interaction might play a role in the pathogenesis of other diseases, including sarcoidosis.  
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BACKGROUND 
Tuberous sclerosis complex (TSC) is a rare genetic disorder, characterized by predominantly benign 
tumours developing potentially in all organ systems. Pulmonary involvement consists of 
Lymphangioleiomyomatosis (LAM) and Multifocal Micronodular Pneumocyte Hyperplasia 
(MMPH), which cause cystic and nodular diseases, respectively. Pneumothorax and chylothorax are 
common clinical presentations of LAM, whereas MMPH is usually asymptomatic. Here we describe 
a female with TSC and LAM with new pulmonary findings. 
 
CASE PRESENTATION 
A 47-year-old woman, affected by TSC with a mutation identified in the TSC1 gene [c.682C>T 
(p.Arg228*)], was referred to the TSC Clinic of San Paolo Hospital (Milan, Italy). Family history 
was noticeable for Addison’s disease and brain glioblastoma (in her mother) and idiopatic pulmonary 
fibrosis (in her father). Her daughter was affected by TSC. The patient suffered from primary biliary 
cirrosis/autoimmune hepatitis overlap syndrome. She was treated with ursodeoxycholic acid (15 
mg/kg/day). 
She received a diagnosis of LAM by chest CT scan, which showed bilateral lung cysts 
randomly distributed thoughout the lungs. Chest CT scan revealed also the presence of sclerotic bone 
lesions. Pulmonary function tests were normal, such as the 6-minutes walking test. Vascular 
endothelial growth factor (VEGF)-D, a lymphangiogenic growth factor proposed as a biomarker for 
LAM diagnosis and severity, was 582 pg/mL (normal limits 153-642 pg/mL). Dermatological 
examination showed hypomelanotic macules, facial angiofibromas, xantelasma palpebrarum, 
periungual fibromas and erythematous plaque on the left knee. She had a renal angiomyolipoma of 
4.2 cm in the left kidney. Brain magnetic resonance (MR) showed the presence of cortical tubers. 
There was no ocular or heart involvement. 
One year later, the patient was adressed to our clinic. A new high resolution chest CT scan 
(HRTC) was performed, and confirmed the presence of both multiple cysts and micronodular 
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opacities, consistent with MMPH. Multiple hilar-mediastinal lymphadenopathies were also 
identified. Of note, hilar lymphadenopathies were symmetrically enlarged (Figure 1). 
Simultaneously, subcutaneous nodules appeared on the patient’s forearm bilaterally (Figure 1E), 
prompting a biopsy that resulted in the hystopathologic diagnosis of non-necrotizing granulomas, 
with mono- and multinucleate epithelioid cells, some of them with asteroid bodies surrounded by a 
sparse lymphocytic infiltrate, suggestive of granulomatous dermatitis with sarcoid-like granulomas. 
Diseases other than sarcoidosis were ruled out by second line evaluations on histology samples, such 
as Ziehl-Neelsen, periodic acid-Schiff (PAS), and Giemsa staining techniques. Immunologic studies 
showed positive antimitochondrial antibody and antinuclear antibody (titre 1:1,280, speckled 
pattern). IgG, IgM and IgA levels resulted within normal range. HIV test was negative. Other causes 
of granulomatous disease such as drug-induced hypersensitivity, pneumoconiosis, pulmonary 
histiocytic disorders, diseases associated with vascular inflammation were ruled out through clinical 
history, examination and the results of instrumental tests. 
Thus, a diagnosis of sarcoidosis was considered. In order to evaluate the extent of the disease, 
laboratory tests were performed and showed normal serum angiotensin conversion enzyme (ACE) 
and serum and urinary calcium levels. Abdominal ultrasonography showed an enlarged liver with 
irregular edges and nodular heterogeneous echotexture, with mild steatosis and multiple renal cysts 
without evidence of nephrolithiasis. Bilateral x-ray of the hands did not show alterations in bone 
structure. The ophthalmologic examination, including funduscopic evaluation showed no signs of 
uveitis and confirmed the absence of retinal hamartomas and achromic patches related to TSC. EKG 
and echocardiography showed no abnormalities. Pulmonary function tests, including spirometry and 
lung volumes were normal; a mild reduction in diffusing capacity for carbon monoxide was detected. 
The six-minute walk test was normal. A diagnosis of stage I pulmonary sarcoidosis was made.. No 
treatment for sarcoidosis was initiated since the patient had neither systemic involvement, nor 
respiratory impairment. A treatment with Sirolimus was not performed due to the limited pulmonary 
cystic involvement and the lack of respiratory symptoms, and a clinical follow-up was carried on.  
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DISCUSSION AND CONCLUSIONS 
This case report represents the first description of the coexistence of three rare disorders: autoimmune 
hepatitis/primary biliary cirrhosis overlap syndrome, TSC/LAM, and sarcoidosis. The presence of 
more than one rare disease should challenge the concept of a potential common underlying 
mechanism. 
Lymphadenopathy, both thoracic and abdominal, has been described as another possible 
feature of LAM. For instance, a recent study on 138 patients with LAM, both sporadic and associated 
with TSC, found a prevalence of 9.4% for mediastinum and pulmonary hilum lymphatic lesions 23. 
However, the presence of granulomatous skin lesions has not yet been described in LAM associated 
with TSC. Thus, the results of the skin biopsy together with the presence of bilateral hilar 
lymphadenopathy lead to the diagnosis of sarcoidosis.  
With respect to sarcoidosis, the importance of host susceptibility and gene-environment 
interaction is widely accepted 24. Although sarcoidosis does not meet the criteria for autoimmune 
disease, it can coexist with a wide range of autoimmune disorders, including primary biliary cirrhosis, 
which is characterized by either hepatic granuloma formation of cutaneous granulomatous 
inflammation, connective tissue diseases (e.g. systemic sclerosis and Sjogren’s syndrome), Addison’s 
disease, and thyroiditis 25. It is noteworthy that the diagnosis of sarcoidosis in case of granulomatous 
skin lesions is made by exclusion criteria. Granulomatous lesions have been described in case of 
granulomatous-lymphocytic interstitial lung disease (GLILD) associated with common variable 
immunodeficiency (CVID), drug toxicity, or infections such as tuberculosis or fungal infections. All 
the aforementioned diagnoses were ruled out in our patient. As previously stated, the association 
between granulomatous lesions and autoimmune hepatitis/PBC, such as other immune-mediated and 
chronic inflammatory disease, has been previously described 26.  
TSC is an autosomal-dominant disease caused by heterozygous loss-of-function mutations in 
the TSC1 (chromosome 9q34) or TSC2 (chromosome 16p13) tumour suppressor genes coding for 
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hamartin and tuberin, respectively. Tuberin and hamartin, together with TBC1D7, form a complex 
that functions as a negative regulator of mammalian target of rapamycin (mTOR) through the 
inhibition of Rheb. Inactivation of TSC1 or TSC2 results in overactivation of mTOR leading to 
abnormal cell growth, proliferation, metabolism, and angiogenesis. A common molecular mechanism 
for LAM/TSC and sarcoidosis is not known. However, a strong immunoreactivity for cathepsin-k 
was demonstrated in spindle and epithelioid-shaped cells of lung LAM and in granulomas of 
sarcoidosis cases 27. Since it is known that modulation of cathepsin-k may occur through the mTOR 
pathway, it is possible to speculate that the mTOR pathway might play a role in sarcoidosis 28. Several 
evidences demonstrated an integration of signaling of the mTOR pathway and mitogen-activated 
protein kinases (MAPKs)-Erk activation. For instance, vascular endothelial growth factors (VEGF)-
C, a lymphangiogenic growth factor present at high levels in serum and urine of patients with LAM, 
induces phosphorylation of Akt, mTOR, S6K, S6 and MAPK-Erk. Uncontrolled inflammation and 
chronic inflammatory diseases may be caused by the persistent activation of MAPKs, which can 
occur in sarcoidosis 29. This finding suggests an explanation for the persistent production of several 
inflammatory cytokines, such as TNF-α and IL-12, in sarcoidosis. Interestingly, Linke et al. found 
that activation of mTORC1 due to TSC2 deficiency causes granulomatous disease, including 
sarcoidosis, in both mice and humans. mTORC1 inhibition resolves granulomas in TSC2-deficient 
mice, suggesting that treatment with mTOR inhibitors, used to stop the progression of benign tumors 
and LAM in TSC, might improve the signs of sarcoidosis as well 30. However, the reason why not all 
patients with TSC develop sarcoidosis is still unknown.  
Although at present it is not possible to demonstrate a common mechanism underlying 
LAM/TSC, sarcoidosis, primary biliary cirrhosis and autoimmune hepatitis, and their coexistence 
could well occur by chance, we might speculate that the dysregulation of the pathway involving 
mTOR and MAPK and their interaction may play a role in the alteration of the diseases. Further 
reports are needed to demonstrate our hypothesis.  
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FIGURE 1 
 
 E 
Figure 1: (A) The mediastinal window HRCT image shows symmetrical hilar and subcarinal 
enlarged lymphnodes. (B-D) HRCT images show scattered lung cysts (arrows) consistent with 
lymphangioleiomyomatosis and either solid or subsolid micronodules (circles). (E) Multiple 
subcutaneous painless, hard papules and nodules covered by eritematous skin on the left foreararm 
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CHAPTER III: EVALUATION OF SERUM BIOMARKERS IN S-LAM AND TSC 
 
VASCULAR ENDOTHELIAL GROWTH FACTORS AND MATRIX METALLOPROTEINASES 
SERUM LEVELS FOR LAM DIAGNOSIS IN PATIENTS WITH SPORADIC LAM AND 
TUBEROUS SCLEROSIS COMPLEX 
 
ABSTRACT 
 
Lymphangioleiomyiomatosis (LAM) is a rare cystic disease affecting primarily young women. It 
could develop in a sporadic form (S-LAM) and in women with tuberous sclerosis complex (TSC). 
Serum level of vascular endothelial growth factor D (VEGF-D) higher than 800 pg/mL in presence 
of typical air cystic changes in pulmonary parenchyma evaluated with the high resolution chest CT 
scan is diagnostic. Matrix metalloproteinases (MMPs) are extracellular matrix-degrading enzymes 
that might have a role in cystic lung destruction and in the process of migration of LAM cells. 
We assessed serum levels of VEGF-D, VEGF-C, MMP-2 and MMP-7 in a cohort of Italian patients 
affected with S-LAM and TSC with and without LAM with the aim to explore their role as biomarkers 
of LAM.  
Serum level of VEGF-D and C, MMP-2 and -7 were quantified by ELISA assays for 52 adult women 
with S-LAM and TSC and for 16 controls. ROC curves were built to explore diagnostic potential of 
single biomarkers. VEGF-D, MMP-2 and MMP7 were higher in patients with LAM than in patients 
without; there was no difference in VEGF-C levels between groups. All healthy controls had VEGF-
D level less than 800 pg/mL ROC curves analysis confirmed the VEGF-D as the biomarkers with the 
high accuracy for LAM diagnosis and showed that MMP-2 and MMP-7 could be a promising 
biomarker of LAM.  Patients with VEFG-D higher than diagnostic threshold of 800 pg/mL show 
more frequently chilothorax and mutation in TSC2 gene than patients with lower VEGF-D levels 
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while there was no difference regarding MMP-2 and MMP-7 in systemic involvement, except for a 
higher frequency of cortical tubers in patients with high MMP-7. 
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INTRODUCTION  
 
Lymphangioleiomyiomatosis (LAM) is a rare progressive disease affecting mostly women in 
childbearing age1. The disease is characterized by abnormal smooth muscle-like cell (LAM cells) 
proliferation in the pulmonary interstitial and along the axial lymphatics in thorax and abdomen, 
which could lead to vascular, and airways obstruction and consequent air cystic development2. The 
disease is clinically characterised by progressive dyspnoea, recurrent pneumothorax, and chylous 
pleural effusions and, in most cases it could lead to respiratory failure1. LAM could develop in both 
a sporadic form (S-LAM) involving lungs, lymphatics and kidney and in patients affected by tuberous 
sclerosis complex (TSC), a rare tumor-suppressor syndrome associated with hamartomas in multiple 
organs, seizures and cognitive impairment (TSC-LAM)3.  
Vascular endothelial growth factor (VEGF) is an angiogenic growth factor produced by malignant 
cells.  The “D” and “C” isoform of VEGF, the ligands for the lymphatic-growth factor receptor 
VEGFR-2 and VEGFR-3/Flt-4, induce formation of lymphatics and promote the spread of tumour 
cells to lymph nodes. Serum VEGF-D levels are increased in most LAM patients and in presence of 
characteristic cystic changes at chest CT scan, a serum level ≥ 800 pg/dL is considered diagnostic, 
thus avoiding invasive assessment such as pulmonary biopsy4. The VEGF-D level was associated to 
disease severity evaluated as presence of chylous effusions and/or lymphatic involvement5,6 however 
a strong correlation between VEGF-D and the extent of the parenchymal involvement evaluated with 
chest CT scan has been observed but not completely demonstrated5,7. Furthermore VEGF-D is not 
indicative of disease activity8.  LAM cells are immune reactive for VEGF-C, but previous studies 
demonstrated that the serum level in LAM patients as compared with age and gender matched controls 
does not differ9.  
Matrix metalloproteinases (MMPs) are extracellular matrix-degrading, zinc-dependent enzymes 
active in lung tissue remodelling and repair that have caught attention in the pathogenesis of cystic 
lung destruction and in the process of migration of LAM cells10. MMPs are components of ECM that 
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degrades matrix substrates such as elastin and collagen in the lung parenchyma and their impairment 
has been implicated in the pathogenesis of several lung diseases including COPD, asthma, idiopathic 
pulmonary fibrosis and Langerhans cell istiocytosis 11,12. Immunochemical studies showed that 
MMP-2 and MMP-9 are expressed in LAM cells13,14 but serum levels of the former and not of the 
latter were significantly higher in patients with LAM patients compared to healthy controls14. 
However, the role of MMPs in LAM is controversial and other studies suggest that serum MMP-9 
and MMP-2 levels cannot be correlated with extent of pulmonary cystic involvement7. LAM is a 
slowly progressive neoplasm that targets the lungs and presents pathogenic mechanisms similar to 
cancer, i.e. metastasis via blood and lymphatic circulation, infiltration and invasion.  In a TSC model 
and in LAM tissues the invasion of tuberin-null cells might be mediated by MMP-7, a component of 
cell invasion15.  
The aim of the present study was to explore the role as biomarkers of MMP-2 and MMP-7 in a cohort 
of patients with S-LAM and with TSC with or without LAM, or TSC-LAM minimal disease, and 
confirm diagnostic value of VEGF-D in LAM. 
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METHODS 
 
Study design and population 
 This was a cohort study involving adult women affected by S-LAM and TSC evaluated at the 
Tuberous Sclerosis Centre of San Paolo Hospital, Milan, Italy, from 2014 to 2017. LAM is diagnosed 
according to ERS criteria and TSC is diagnosed according to clinical and genetics criteria16,17,18. 
During the first visit every systemic manifestation of TSC was evaluated by specialists experienced 
in TSC diagnosis and management (neurologist, pulmonologist, nephrologist, dermatologist, 
ophthalmologist, radiologist, and cardiologist) according with international guidelines as previously 
reported1918 and the follow up is established, if needed. All patients with a suspicious of LAM or a 
definite diagnosis of LAM16 coming primarily from pulmonary clinic were also evaluated in the TSC 
clinic to find out a possible form of TSC-LAM. Clinical, radiological and genetic data collected in 
the year of the biomarkers analysis were analysed and compared to biomarkers serum levels results. 
All patients were in an observational cohort with Hospital Ethics Committee approval. All patients 
or relatives, in case of patients with intellectual disability, provided informed consent.  
 
Quantification of serum VEGF-D, VEGF-C, MMP-2 and MMP-7 
 Blood was collected in serum separator tubes, allowed to clot for 30 min at 4°C, centrifuged 
at 1000 x g for 15 min. Serum was aliquot and stored at -80°C. Serum VEGF-D, VEGF-C, MMP-2 
and MMP-7 were measured using Quantikine Human Immunoassays (R&D Systems; Minneapolis, 
MN) according to the manufacturers’ instruction. Measurements were performed in duplicates.  
 
Pulmonary, radiological, systemic involvement and genetics 
 Every systemic sign of TSC was investigated and evaluated as reported elsewhere 19. For 
patients with TSC, thoracic high-resolution lung CT (HRCT) was performed in women [1]: 1) at the 
age of 18 years for the patients diagnosed with TSC in pediatric age; 2) at the moment of TSC 
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diagnosis in adult patients or during the first evaluation in our centre; 3) in case of respiratory 
symptoms. Spirometry, body pletismography and lung diffusion tests (Platinum EliteTM MGC 
Diagnostic, USA) were performed according to ATS/ERS guidelines20,21. The six- minute walk test 
(6MWT) was performed along a flat, straight, 30 meters walking course supervised by a well-trained 
researcher according to ATS guidelines22. Neurological manifestations were evaluated by the use of 
CT and brain magnetic resonance imaging (MRI). Epilepsy and neurodevelopmental 
psychiatric/cognitive symptoms were also evaluated. For abdominal manifestations, patients were 
evaluated at least once with an abdomen CT or MRI, and followed-up with ultrasonography (US) in 
the majority of cases. TSC related skin lesions were also clinically evaluated. Cardiac involvement 
was investigated by electrocardiography and echocardiography. Extensive explanation of genetic 
analysis was previously reported19. Patients were classified as having mutation in TSC1, TSC2 gene 
and when genetic analysis was inconclusive, they were classified as having no mutation identified 
(NMI). 
 
Interpretation of radiology 
All chest CT scan performed in the year of serum analysis were re-evaluated by a radiologist 
experienced in LAM, blinded to other researchers. The severity of cystic lung disease was graded 
according to a visual quantitative grading system23. The radiologic involvement was classified as 
“minimal” (Grade 0) if patients showed less than 10 lung cysts. If more than 10 cysts were identified 
then the extent of cysts was graded as ”mild” disease (grade 1) if less than one third of the lung was 
involved, “moderate” (grade 2) if one to two thirds of the lungs resulted involved and “severe” (grade 
3) if cysts involved more than two third of the lungs. Lymphatic involvement was considered if there 
was the presence of: lymph node enlargement, pleural effusion attributed to cylothorax or 
lymphangioleiomyomas. 
 
Statistical analysis  
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 The results are shown as median and interquartile range (IQR), unless otherwise stated. 
Lilliefors corrected K-S test was performed before the data analysis in order to examine the 
distribution of the residuals of the parametric tests. For comparisons between patients, the Wilcoxon 
rank-sum test, Mann-Whitney test and Kruskal-Wallis test were used, as appropriate.  The ROC curve 
was used to choose the optimal cut off point at which the sensivity and specificity of every biomarker 
were maximized.  
All tests were two-sided, and p < 0.05 were considered statistically significant. Statistical tests were 
performed using the Statistical Package for Social Sciences (version 21.0; SPSS, Chicago, IL) and 
GraphPad Prism 7 (GraphPad Software, San Diego, California, USA). 
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RESULTS 
Characteristics of study subjects 
 Data from sixty-eight adult women with a median age of 32 years (median, IQR: 29-46) were 
considered (Figure 1). Two patients with TSC were excluded from the study because of the lack of 
thoracic imaging (chest CT scan was requested during the first pulmonology evaluation but the 
patients were lost at follow up). Data from 66 patients were available for the analysis; the analysis of 
serum from 16 healthy female volunteers was also performed (Figure 1). 13 patients (19%) were 
affected by S-LAM, 37 (54%) by TSC, and of these 14 (38%) had TSC-LAM. Six patients with TSC 
had a chest CT showing less than 10 parenchymal cysts and they were classified as having a TSC-
LAM “minimal disease”16. In patients with S-LAM the diagnosis was istologically confirmed in 9 
patients (by pulmonary biopsy in 7 patients, by biopsy of abdominal lymphangioma in 1 patient and 
by identification of LAM cells in the chylous effusion in 1 patient). In 3 patients with S-LAM the 
diagnosis was confirmed by the presence of a chest CT scan compatible in association with evidence 
of renal angiomyolipoma24. There was no difference in the median age and in the age at LAM 
diagnosis between groups. Six patients currently smoke and 36 have a smoking history. All patients 
affected with LAM, both S-LAM and TSC-LAM were taking standard therapy (long acting B2 
agonists and long acting muscarinic agents). None was treated with sirolimus or everolimus at the 
time of biomarkers analysis.  
The demographic, clinical and genetic characteristics of the study population are reported in Table 
1.  The median values of VEGF-D in whole population was 515 pg/dL (interquartile range, IQR,: 364 
pg/dL -1407 pg/dL), the median values of VEGF-C was 6342 pg/dL (IQR: 5142 pg/dL -7613 pg/dL), 
the median value of MMP-2 was 285 ng/dL (IQR: 221 ng/dL -348 ng/dL), the median value of MMP-
7 was 3,63 ng/dL (IQR: 3,03 ng/dL -4,84 ng/dL). 
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Distribution of serum biomarkers between groups 
 Figure 2 shows the distribution of the biomarkers between subjects. Serum VEGF-D was 
higher in S-LAM (median value: 1456pg/ml range 457-3167pg/ml) and TSC-LAM (median value: 
1057pg/ml range 574-3302pg/ml) than in TSC patients (median value: 396 pg/ml, range 322-
646pg/ml) and controls (median value: 378 pg/ml range 335-444pg/ml), (p<0.001) (Figure 2). All 
healthy controls had a VEGF-D lower than 800 pg/mL. Among patients with TSC, 1 patient showed 
borderline serum VEGF-D level while 2 patients had very high level even without any identified cysts 
at chest CT scan. Three patients between the 6 classified as having “minimal LAM-TSC” had serum 
VEGF-D higher than 800 pg/mL. When considering comparison between each subgroup, VEGF-D 
remains significantly higher in S-LAM, TSC-LAM and minimal LAM TSC compared in healthy 
controls (p=0.014, p=0.005, p=0.034) but not in TSC compared to healthy controls (p>0.999); Figure 
2. VEGF-D did not differ between TSC and LAM-TSC (p=0.055) and between TSC and minimal 
LAM TSC (p=0.170). Serum VEGF- C did not show any significant difference between the groups. 
As previously reported8, VEGF-C in serum was slightly lower in S-LAM patients (median value: 
6453 pg/ml, range 585-8325 pg/ml), TSC-LAM patients (median value: 6230 pg/ml, range 5240-
7411 pg/ml), and TSC patients (median value: 6338 pg/ml, range 4271-7718 pg/ml) than controls 
(median value 7058 pg/ml, range 5093-8198 pg/ml) (Figure 2).  
Considering all LAM patients (both S-LAM and LAM-TSC) compared with subjects without LAM 
(controls and TSC patients) serum MMP-2 was higher in the former [median value: 301 ng/ml (276-
463 ng/ml) vs 231ng/ml  (213-324 ng/ml), p=0.001] but with a high overlap between the values (data 
not showed).  
Serum MMP-2 levels were higher in S-LAM (median value: 298 ng/ml, range -416 ng/ml)], and TSC-
LAM patients (median value: 293 ng/ml (248-480 ng/ml)] compared to healthy volunteers [median 
value: 225 ng/ml (203-336 ng/ml)] and TSC patients [median value: 232 ng/ml (213-323 ng/ml), 
p=0.020] (Figure 2). When considering pairwise analysis, MMP-2 did not differ in S-LAM, TSC-
LAM and minimal LAM TSC compared to healthy subjects (p=0.101, p=0.475, p=0.271 respectively) 
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nor between TSC and LAM-TSC (p=0.977) or between TSC and minimal LAM TSC (p=0.05); 
Figure 2. Serum MMP-7 was higher in patients with LAM (both S-LAM and TSC-LAM) than in 
patients with TSC and in healthy subjects [median value: 4,5 ng/ml (3,3-5,3 ng/ml) vs 3,4 ng/ml (2,8-
3,8 ng/ml), p=0.002]. A high overlap between the values is observed. MMP-7 serum levels were 
higher in TSC-LAM patient [median value: 4,78 ng/ml (3,5-5,3 ng/ml)] with even greater values in 
patients with TSC-LAM minimal disease [median value: 5,69 ng/ml (4,90-7,43 ng/ml)] than in S-
LAM patients [median value: 3,39 ng/ml (3,16-4,35)] and in controls [median value: 2,99 ng/ml 
(2,62-3,59 ng/ml); p=0.001] (Figure 2). When considering pairwise analysis, MMP-7 is significantly 
higher in LAM-TSC and minimal TSC-LAM than in healthy subjects (p=0.008 and 0.001 
respectively) but did not differ between S-LAM and healthy subjects (p>0.99) and between S-LAM 
and TSC-LAM (p>0.99); Figure 2. 
 
Diagnostic yield of serum biomarkers 
 When considering patients with LAM (both S-LAM and TSC-LAM and with TSC-LAM with 
minimal disease) and healthy subjects, with the cut off value of 800 pg/mL the VEGF-D sensitivity 
and specificity for the diagnosis of LAM in our sample was 58% and 100% respectively with a 
negative likehood ratio of 0.42, a positive predicted value of 100% and a negative predicted value of 
53% and an accuracy of 71%. ROC analysis confirmed VEGF-D as an effective diagnostic test to 
predict LAM [area under curve (AUC): 0.879±0.049 (95% CI:0.782-0.975), p<0.001] (Figure 3). 
The ability of MMP-2 for predicting LAM disease was lower than the ability of VEGF-D with an 
AUC of 0.756±0.079 (95% CI:0.601-0.910), p=0.004 for LAM. With a cut off value of 263,18 pg/ml, 
the sensitivity for LAM was high but the specificity remains low (81% and 69% respectively) (Figure 
3). ROC analysis showed that MMP-7 was a better biomarker for diagnosis of LAM than MMP-2 
with an area under curve of 0.828±0.060(95% CI:0.710-0.945), p<0.001, for LAM. The optimal cut 
off value for LAM resulted as 3,27 pg/ml; the sensitivity was 67% and specificity 82% (Figure 3). 
Diagnostic yield of biomarkers for LAM in TSC patients 
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 Considering all patients with TSC, the specificity of the cut off value of 800 pg/dL for LAM 
was 82% and the sensitivity remaining quite low (55%). The area under ROC curve for LAM 
diagnosis was 0.791±0.077(95% CI:0.640-0.941), p=0.003 (Figure 3). The diagnostic yield of MMP-
2 in predicting LAM disease in patients with TSC was lower than the ability of VEGF-D. In fact the 
area under curve was 0.694±0.088 (95% CI:0.521-0.867), p=0.044; considering a cut off value of 
339.8 pg/dL the specificity of MMP-2 was high but the sensitivity remains low (88% and 40% 
respectively). In this subgroup of our cohort the diagnostic yield of MMP-7 for LAM diagnosis was 
similar to MMP-2 with a area under curve of 0.713±0.090 (95% CI:0.538-0.889), p=0.027. The 
optimal cut off value for LAM resulted 4.0 pg/mL with a sensitivity of 75% and a specificity of 71%. 
 
Role of biomarkers for TSC genetic, systemic and LAM radiological involvement 
 Patients with a VEGF-D higher than 800 pg/mL were significantly younger; they were 
diagnosed with LAM at a younger age and had more frequent chylothorax (p=0.034) than patients 
with a VEGF-D serum level lower than 800pg/ml (Table 2). The VEGF-D level above 800 pg/ml 
was related to higher MMP-2 and MMP-7 values (p<0.001 and p=0.001, respectively, data not 
shown), and to a high frequence of mutation in TSC2 gene. In patients with higher VEGF-D the renal 
angiomyolipomas were bigger (p=0.002) and the retinic hamartomas were more frequent (Table 2) 
but there was no significant differences in the respiratory function tests (Table 2b).  
Since there are no previous work that have analysed a link between MMP-2 and MMP-7 and systemic 
involvement, we divided the patients in two groups based on serum level higher or lower of the 
50°percentile of the distribution of the biomarker in the whole population in study. Systemic 
involvement and functional results did not differ between patients with MMP-2 and MMP-7 higher 
or lower than 50 percentile (Table 3; 3a and Table 4; 4a) except for a higher frequency of cortical 
tubers in patients with high MMP-7. Based on revised HRTC scan data, 6 patients have a “minimal” 
disease, 12 patients had “mild” disease, 5 patients had “moderate” disease and 5 patients had “severe” 
disease. There were no differences in radiological involvement according to serum VEGF-D (Table 
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2). A more severe radiological involvement was seen in patients with MMP-7 lower than 50° 
percentile compared to patients with MMP-7 serum level higher than 50° percentile (Table 4). 
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DISCUSSION 
The most important results of our work are: 
1) VEGF-D is confirmed as biomarker of LAM with a high specificity; the specificity decreases in 
patients with TSC. Patients with LAM-TSC tended to show higher levels of VEGF-D than patients 
with TSC without pulmonary involvement. 
2) MMP-2 and MMP-7 serum levels differ patients with and without LAM but a high overlap of the 
single values between groups is observed; the diagnostic yield of this two biomarkers for LAM is 
lower than the diagnostic yield of VEGF-D. 
3) Higher level of VEGF-D seems to be related to a higher frequency of chilothorax, ocular 
involvement and to the presence of the mutation in TSC-2 gene. 
 
 VEGF-D serum level were analysed in a couple of previous studies that brought this 
biomarker to be inserted in the recent diagnostic guidelines as a diagnostic tool in presence of a typical 
chest CT scan framework, thus reducing the need for lung biopsy in patients with suspected LAM4. 
In two studies developed by Seyama K et al and Glasgow CG et al respectively in 2006 and 2009, 
VEGF-D serum levels were significantly higher in LAM patients that in controls9,6. In 2013 Xu et al 
found similar results with serum VEGF-D level significantly increased in definite LAM group, 
compared with that of healthy controls25. Successively, Young et al measured serum level of VEGF-
D in patients with LAM, healthy controls and patients with other pulmonary diseases and found a 
serum level of VEGF D significantly higher in the first group of patients. Similarly Radzikowska et 
al showed that VEGF-D could discriminate between LAM and other pulmonary cystic diseases such 
as pulmonary Langerhans cell histiocytosis and lymphocytic interstitial pneumonia26. Our data 
showed higher VEGF-D serum levels in LAM patients than in healthy controls, in line with this data. 
Nevertheless in our study group, more than 40% of patients with a definite diagnosis of LAM showed 
serum levels of VEGF-D lower than the diagnostic threshold of 800 pg/mL; VEGF-D has a sensitivity 
of 58% and a specificity of 100% for the diagnosis of LAM. VEGF-D high specificity is confirmed 
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with a low sensitivity. This is in line with the study by Chang in which 42% of patients with LAM 
showed VEGF-D serum level lower than the diagnostic threshold and a sensitivity of 56% and a 
specificity of 100%27. On the contrary, Xu et al find a VEGF-D sensitivity of 96%5. In a study from 
Glasgow CG at al, a statistically significant difference between LAM and healthy control for VEGF-
D serum level was maintained only for LAM patients with lymphatic involvement 
(lymphangioleiomyomas and/or lymphadenopathy) and not for those patients with a disease restricted 
to the lung6.  In our analysis however we do not find any difference in lymphatic involvement in 
patients with a VEGF-D higher or lower the diagnostic threshold of 800 pg/mL except for 
chylothorax, that could be linked to lymphatic involvement, more frequent in patients with a VEGF-
D higher than 800 pg/mL. However it is possible that these results could be related to some 
differences in the studied population. The differences in the number of patients involved in the studies 
could in part explain these differences and affect the statistical significance. Furthermore in our cohort 
there was a low percentage of lymphatic involvement.  
We find a trend to higher VEGF-D serum levels in patients with TSC-LAM respect to patients with 
TSC and a normal high-resolution CT scan. This is in line with data published by Young L et al in 
2008. In that study in fact VEGF-D levels were much higher in women with the tuberous sclerosis 
complex and LAM than in women with the TSC and normal high-resolution CT scan. However 
authors find a very strong difference between two groups in contrast to our data that shows only a 
trend to statistical significance. This difference may be ascribed to some differences in the studied 
population as well. In fact the majority of our patients with LAM has a mild disease while we do not 
have data on the population analysed in Young’s study. Furthermore TSC is a disease with a very 
heterogeneous presentation and systemic involvement and the extent of lymphatic involvement could 
have influenced the analysis.  
The MMPs and their tissue inhibitors (TIMPs) in vivo are involved in remodelling the extracellular 
matrix and basement membranes both in normal and pathologic conditions. There are not previous 
data about the level of isoform MMP-7 in human, while the isoform MMP-2 has been deeply 
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investigated and some works are available in scientific literature with quite contrasting results. Some 
immunohistochemical studied have demonstrated in fact that the expression of MMP-2 and their 
tissue inhibitors is over expressed in pulmonary tissue from patients with LAM compared to normal 
bronchial tissue13,28. Lee et al demonstrated that cells lacking TSC1/TSC2 genes, over expressed 
MMP-2 and that this overexpression was not affected by rapamycin (a inhibitor of the  activation of 
T cells and B cells by reducing their sensitivity to interleukin-2 (IL-2) through mTOR inhibition)27.  
From these observations a possible role of matrix metalloproteinases in the development of 
parenchymal air cysts in LAM was proposed. Our data indicated that the MMP-2 serum levels are 
higher in patients with LAM than in patients without LAM but we also observed a high overlap 
between subgroups of the single values. These data are consistent with the previous studies on this 
field. Moses et al described a case of a patient with LAM in which urinary levels of some isoform of 
MMPs (in particular MMP-2 and -9) were elevated and decrease after a treatment with doxycycline 
(an MMP inhibitor) 29; Pinheiro Pimenta et al described a group of 41 patients also treated with 
doxycycline. Serum and urinary levels of MMP-2 were higher in patients with LAM then in healthy 
controls and decreased after treatment with the antibiotic; however the median of MMP-2 in serum 
was below the detection limit both at baseline and after treatment 29 30. Chang and colleague analysed 
some serum biomarkers as diagnostic and prognostic tools and found higher MMP-2 levels in patients 
with LAM than in controls with a considerable overlap of single values between the two groups. 
Finally Odajama et al studied in 2009 serum level of MMP-2 and MMP-9 in 36 patients with LAM 
and did not find any significant differences from healthy controls27. ROC analysis have demonstrated 
that, in line with the previously cited work by Chang et al, the ability of MMP-2 for predicting LAM 
disease was lower than the ability of VEGF-D. 
Our data indicated that patients with VEGF-D serum level above the diagnostic threshold of 800 
pg/ml show more frequent mutation in TSC 2 gene. This is consistent with previous studies that have 
indicate that in patients with TSC- LAM there is a higher rate of mutation in TSC2 gene respect to 
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TSC131,32,33 and that that patients with TSC and a mutation in TSC1 gene have a milder disease in 
comparison with patients showing a mutation of TSC2 gene34. 
This work has two innovative characteristics: firstly we made deep phenotyping of the whole 
population analysing separately and comparing the serum level of four biomarkers in patients with 
S-LAM and TSC-LAM and exploring a possible link with clinical and genetic characteristic of the 
single groups. Secondly this is the first work that have analysed serum level of MMP-7 in relationship 
to LAM. A number of potential limits of the present study deserve also discussion. First, our data are 
about a single centre cohort of patients. Secondly, our patients show a relatively mild disease, in terms 
of pulmonary function. Third, the clinical and radiological data used to explore a possible link 
between single biomarkers and systemic involvement were requested for clinical follow up purpose 
and due to the “retrospective” characteristic of the analysis some data are missing.  
 
CONCLUSIONS 
The diagnostic value of VEGF-D for LAM was confirmed in this cohort of Italian patients. VEGF-D 
specificity decreases considering TSC patients, probably due to lymphatic involvement linked to 
TSC. MMP-2 and especially MMP 7 are promising biomarkers for LAM but validation in 
longitudinal studies and with a larger patient population is needed. 
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FIGURES 
 
Figure 1. Population in analysis  
 
 
 
 
LAM: lymphangioleiomyomatosis, TSC: tuberous sclerosis complex, minimal disease: patients with less than 10 cysts identified at chest CT scan 
 
 
 
 
 
  
Analysed serum
N=68
S-LAM
N=13 (20%)
TSC-LAM 
N=14 (23%)
LAM-TSC 
minimal disease 
N= 6 (8)
TSC
N=17 (26%)
HEALTHY 
VOLUNTEERS 
N=16 (24%)
Chest CT scan 
not available,  
N=2
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Figure 2 Distribution of VEGF-D (A) p<0.001, VEGF-C (B) p=0.354, MMP-2 (C) p=0.040 and MMP-7 (D) p=0.001 in the 4 subgroups of patients 
and in healthy volunteers 
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Figure 3 Model representing the diagnostic ability of serum VEGF-D, MMP-2 and MMP-7 for predicting LAM disease (A) in a sample of patients 
with LAM (both S-LAM and TSC-LAM) and healthy volunteers and (B) in a sample of subject with TSC with and without LAM. A larger AUC 
indicates higher accuracy for diagnosis of LAM.  
.  
 
 
 
A B  
 
(A) VEGF-D was an effective diagnostic test to predict LAM [area under curve (AUC): 0.879±0.049 (95% CI:0.782-0.975), p<0.001] continuous 
line, respect to MMP2 [AUC: 0.756±0.079 (95% CI:0.601-0.910)], dotted line, and MMP7 [0.828±0.060(95% CI:0.710-0.945), p<0.001], punctuate 
line. (B) Specificity of VEGF-D for LAM disease in TSC patients was lower than in previous analysis but remains significant [AUC: 
0.791±0.077(95% CI:0.640-0.941), p=0.003], continuous line. MMP-2 showed lower accuracy respect to VEGF-D with a AUC of 0.694±0.088 
(95% CI:0.521-0.867), p=0.044, dotted line and similarly MMP-7 showed a AUC of 0.713±0.090 (95% CI:0.538-0.889), p=0.027, punctuate line 
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TABLES 
 
Table 1. Characteristics of the population in analysis 
 
 
S-LAM 
N=13 
TSC-LAM 
N=14 
TSC-LAM 
minimal 
disease 
N= 6 
TSC 
N=17 
HEALTHY 
N=16 
p 
Age, yrs, median (IQR) 36 (31-43) 36 (30-50) 34 (24-63) 32 (24-42) 36 (28-49) 0.831 
Age at LAM diagnosis, yrs, median (IQR) 35 (29-44) 33 (27-45) 29 (22-61) - - 0.930 
Smoke (yes/no/ex), n (%) 
1(9) / 3(27)/ 
7(64) 
2(14) /3(21) 
/9(64) 
1(17) /1(1)/4 
(67) 
1 (6)/ 16 
(94) / 0(0) 
  
Pulmonary involvement and symptoms       
MMPH, n (%) - 8 (57) 6 (100) 10 (59) -  
Dyspnea, n (%) 5 (46) 3 (21) 2 (33) 5 (29) -  
spO2 < 90% during 6mWT, n (%) 4 (36) 3 (21) 0 (0) 2 (12) -  
Respiratory failure, n (%) 0 (0) 0 (0) 0 (0) 0 (0) -  
Pneumothorax, n (%) 4 (36) 3 (21) 1 (17) 0 (0) -  
Chylothorax, n (%)  3 (27) 1 (7) 0 (0) 0 (0) -  
Lymphocele, n (%) 2 (18) 1 (8) 0 (0) 1 (6) -  
Mediastinal lymph node enlargement, n(%) 1 (9) 2 (17) 1 (17) 1 (6) -  
Lymphatic involvement*, n (%) 4 (33) 4 (29) 1 (17) 1 (6) - 0.093 
Abdominal involvement       
Renal angiomyolipomas, n (%) 4 (36) 14 (100) 6 (100) 11 (65) -  
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        n<3/n≥3, n (%) 3(75)/1(25) 1 (7)/13 (93) 1 (17)/5(83) 6 (50)/6(50)   
        <3 cm/≥3 cm, n (%) 2(50)/2(50) 4(29)/10(71) 3(50)/3(50) 7(64)/4(36) -  
Multiple renal cysts, n (%) 1 (9) 8 (57) 3 (50) 6 (35) -  
Hepatic angiomyolipomas, n (%) 1 (9) 6   (43) 1 (17) 5 (29) -  
Genotype       
TSC1, n (%) - 3 (21) 2 (33) 9 (56) - 
0.189 TSC2, n (%) - 7 (50) 4 (67) 5 (31) - 
NMI, n (%) - 4 (29) 0 (0) 2 (13) - 
Systemic TSC involvement       
Renal tumour, n (%) - 1 (8) 0 (0) 4 (24) -  
Renal failure, n (%) 0 (0) 3 (25) 0 (0) 2 (12) -  
Cutaneous involvement, n (%) - 13 (100) 6 (100) 17 (100) -  
Epilepsy, n (%) - 3 (23) 4 (67) 12 (71) -  
Cortical tubers, n (%) - 12 (92) 6 (100) 15 (88) -  
Subependymal giant cell astrocytoma, n (%)  1 (8) 0 (0) 1 (6) -  
*: at least one from chylothorax, lymphocele, mediastinal lymph node enlargement62 
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Table 2. Systemic involvement in patients with TSC and S-LAM according to serum VEGF-D  
 
 
VEGF-D < 800 
pg/mL 
VEGF-D ≥ 
800 pg/mL 
p 
Age at evaluation*, yrs median (IQR) 37(30-49) 32 (26-37) 0.005 
Age at LAM diagnosis, yrs median (IQR) 44 (29-56) 32 (24-36) 0.072 
LAM, n (%) 14 (33) 19 (86) <0.005 
MMPH, n(%)** 13 (57) 10 (67) 0.736 
Dyspnoea, n(%) 11 (42) 4 (19) 0.121 
Pneumothorax, n(%) 3 (12) 5 (24) 0.470 
Chylothorax, n(%) 0 (0) 4 (19) 0.034 
Lymphocele, n (%) 1 (4) 3 (15) 0.209 
Mediastinal lymph node enlargement, n(%) 3 (14) 2 (11) >0.999 
Lymphatic involvement***, n (%) 3 (12) 7 (32) 0.086 
spO2 < 90% during 6mWT, n (%) 5 (20) 4 (19) >0.999 
Genotype**    
TSC1, n (%) 13 (62) 1 (7) 
0.004 TSC2, n (%) 5 (24) 10 (71) 
NMI, n (%) 3 (14) 3 (21) 
Renal AML, n (%), 20 (77) 15 (71) 0.744 
        n<3/n≥3, n (%) 8(40)/12(60) 2(13)/13(87) 0.134 
<3 cm/≥3 cm, n (%) 14(70)/6(30) 2 (13)/13 (87) 0.002 
Multiple renal cysts, n (%) 12 (46) 6 (29) 0.245 
Hepatic angiomyolipomas, n (%) 7 (27) 6 (29) >0.999 
Cutaneous involvement**, n (%) 20 (100) 15 (100) - 
Cortical tubers**, n (%) 17 (85) 15 (100) 0.244 
Epilepsy**, n (%) 9 (45) 9 (60) 0.500 
Arytmia, n(%)** 1 (5) 1 (7) >0.990 
Cardiac rhabdomyoma**, n (%) 3 (15) 4 (31) 0.393 
Fundus oculi abnormalities*, n (%) 2 (10) 6 (43) 0.042 
*age: referred to age at time of blood sample evaluation; IQR: interquartile range; **: Percentage are referred to total patients with TSC; ***: at least 
one from chylothorax, lymphocele, mediastinal lymph node enlargement. MMPH: multifocal micronodular pneumocyte hyperplasia; TSC1/2/NMI: 
mutation of TSC1 TSC2 genes/ no mutation identified; AML: angiomyplipoma 
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Table 2b Functional and radiologic involvement ** in patients with S-LAM and TSC-
LAMaccording to serum VEGF-D  
 
 VEGF-D < 800 pg/mL VEGF-D ≥ 800 pg/mL p 
FEV1, % pred 98 (85-112) 95 (82-101) 0.343 
FVC, % pred 99 (84-110) 94 (78-102) 0.300 
FEV1/FVC, % pred 101 (99-103) 100 (96-106) 0.581 
DLCO, % pred 78 (65-84) 73 (53-82) 0.297 
KCO, % pred 77 (68-80) 73 (59-94) 0.929 
VA, % pred 101 (84-110) 95 (84-117) 0.705 
VR, % pred 86 (65-143) 95 (66-120) 0.888 
TLC, % pred 99 (84-113) 102 (87-112) 0.937 
RV/TLC, % pred 120 (101-128) 135 (103-173)  
TGV, % pred 84 (70-119) 94 (76-125) 0.599 
Radiological severity** 
Minimal disease, n(%) 2 (15) 4 (27) 
 
0.738 
Grade I, n (%) 7 (54) 5 (33) 
Grade II, n (%) 2 (15) 3 (20) 
Grade III, n (%) 2 (15) 3 (20) 
 
**% Data and percentage referred to 28 patients with revised CT scan. FEV1: forced expiratory volume in one second; FVC: forced expiratory 
volume; DLCO: diffusion capacity for CO; VA: alveolar volume; TLC: total lung capacity; RV: residual volume; TGV: thoracic gas volume; %pred: 
% of predicted value. p < 0.050 in bold. 
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Table 3. Systemic involvement in patients with TSC and S-LAM according to serum MMP-2  
 
 
MMP-2 < 50° 
percentile 
MMP2- ≥ 50° 
percentile 
p 
Age at LAM diagnosis, yrs, median (IQR) 44 (24-47) 32 (29-38) 0.582 
Age at evaluation*, yrs, median (IQR) 37 (30-49) 32 (27-41) 0.201 
LAM, n (%) 12 (36) 21 (63) 0.048 
MMPH, n (%)** 12 (63) 12 (60) 0.550 
Dyspnoea, n (%) 8 (38) 7 (26) 0.277 
Pneumothorax, n (%) 4 (19) 4 (15) 0.495 
Chylothorax, n(%) 0 (0) 4 (15) 0.121 
Lymphocele, n (%) 1 (5) 3 (12) 0.622 
Mediastinal lymph node enlargement, n(%) 2 (11) 3 (13) >0.999 
Lymphatic involvement***, n (%) 2 (10) 8 (29) 0.155 
spO2 < 90% during 6mWT, n (%) 3 (15) 6 (22) 0.407 
Genotype**    
TSC1, n (%) 9 (50) 5 (28) 
0.131 TSC2, n (%) 5 (28) 11 (61) 
NMI, n (%) 4 (22) 2 (11) 
Renal AML**, n (%), 16 (76) 19 (70) 0.750 
        n<3/n≥3, n (%) 6 (35)/ 11 (65) 5 (26)/ 14 (74) 0.412 
<3 cm/≥3 cm, n (%) 9 (56)/ 7 (44) 7 (37)/ 12 (63) 0.210 
Bilateral renal AML**, n (%) 10 (48) 16 (62) 0.225 
Hepatic AML*, n (%) 8 (38) 5 (19) 0.192 
Cutaneous involvement**, n (%) - 17 (100) - 
Cortical tubers**, n (%) 14 (82) 19 (100) 0.095 
Epilepsy**, n (%) 7 (41) 12 (63) 0.316 
Arytmia, n (%)** 1 (6) 1 (6) >0.999 
Cardiac rhabdomyoma**, n (%) 2 (12) 5 (29) 0.398 
Fundus oculi abnormalities**, n (%) 3 (18) 5 (28) 0.691 
*age: referred to age at time of blood sample evaluation; IQR: interquartile range; **: Percentage are referred to total patients with TSC; ***: at least 
one from chylothorax, lymphocele, mediastinal lymph node enlargement. MMPH: multifocal micronodular pneumocyte hyperplasia; TSC1/2/NMI: 
mutation of TSC1 TSC2 genes/ no mutation identified; AML: angiomyplipoma 
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Table 3b Functional and radiologic* involvement in patients with LAM (both S-LAM and TSC-
LAM) according to serum MMP2 
 
 
MMP2 < 50° 
percentile 
MMP2 ≥ 50° 
percentile 
P 
FEV1, % pred 98 (85-115) 96 (82-99) 0.516 
FVC, % pred 99 (85-113) 95 (81-103) 0.759 
FEV1/FVC, % pred 101 (99-103) 100 (97-106) 0.288 
DLCO, % pred 79 (66-84) 71 (53-82) 0.383 
KCO, % pred 77 (68-91) 77 (52-85) 0.318 
VA, % pred 102 (78-120) 95 (84-109) 0.720 
VR, % pred 74 (52-108) 116 (76-144) 0.051 
TLC, % pred 90 (82-110) 106 (89-113) 0.026 
RV/TLC, % pred 118 (99-124) 136 (104-179)  
TGV, % pred 75 (66-112) 99 (87-127) 0.058 
Radiological severity 
Minimal disease, n 
(%) 
1 (9) 5 (29) 
 
0.040 
Grade I, n (%) 8 (73) 4 (24) 
Grade II, n (%) 2 (18) 3 (18) 
Grade III, n (%) 0 (0) 5 (29) 
 
*% Data and percentage referred to 28 patients with revised CT scan. FEV1: forced expiratory volume in one second; FVC: forced expiratory 
volume; DLCO: diffusion capacity for CO; VA: alveolar volume; TLC: total lung capacity; RV: residual volume; TGV: thoracic gas volume; %pred: 
% of predicted value. p < 0.050 in bold. 
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Table 4 systemic involvements according to serum MMP-7 
 
 
MMP-7 < 50° 
percentile 
MMP-7 ≥ 50° 
percentile 
P 
Age at evalutation, median (IQR) * 34 (29-45) 37 (28-49) 0.287 
Age at LAM diagnosis, median (IQR) 34 (29-44) 32 (24-52) 0.880 
LAM, n (%) 11 (33) 22 (67) 0.013 
MMPH, n (%)** 5 (36) 19 (76) 0.019 
Pneumothorax, n(%) 4 (21) 4 (14) 0.695 
Dyspnoea, n(%) 6 (32) 9 (31) >0.999 
Chylothorax, n(%) 0 (0) 4 (14) 0.142 
Lymphocele, n (%) 1 (5) 3 (11) 0.632 
Mediastinal lymph node enlargement, 
n(%) 
2 (13) 3 (12) >0.999 
Lymphatic involvement***, n (%) 2 (11) 8 (27) 0.278 
spO2 < 90% during 6mWT, n (%) 4 (21) 5 (18) >0.999 
Genotype**    
TSC1, n (%) 7 (54) 7 (30) 
0.154 TSC2, n (%) 3 (23) 13 (57) 
NMI, n (%) 3 (23) 3 (13) 
Renal angiomyolipomas, n (%), 14 (74) 21 (72) >0.999 
        n<3/n≥3, n (%) 6 (43)/8 (57) 5 (23)/17 (77) 0.273 
<3 cm/≥3 cm, n (%) 8 (57)/6 (43) 8 (38)/13(62) 0.317 
Bilateral renal angiomyolipomas, n (%) 9 (47) 17 (61) 0.390 
Hepatic angiomyolipomas, n (%) 6 (32) 7 (24) 0.741 
Cutaneous involvement**, n (%) 13  (100) 23 (100) - 
Cortical tubers**, n (%) 10 (77) 23 (100) 0.040 
Epilepsy**, n (%) 5 (39) 14 (61) 0.299 
Aritmia, n(%)* 1 (9) 1 (4) >0.999 
Cardiac rhabdomyoma**, n (%) 2 (15) 5 (24) 0.682 
Fundus Oculi abnormalities**, n (%) 3 (23) 5 (23) >0.999 
Multiple retinal hamartomas*, n (%) 1 (8) 5 (23) 0.377 
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*age: referred to age at time of blood sample evaluation; IQR: interquartile range; **: Percentage are referred to total patients with TSC; ***: at least 
one from chylothorax, lymphocele, mediastinal lymph node enlargement. MMPH: multifocal micronodular pneumocyte hyperplasia; TSC1/2/NMI: 
mutation of TSC1 TSC2 genes/ no mutation identified; AML: angiomyplipoma 
 
 
Table 4b Functional and radiologic involvement* in patients with LAM (both S-LAM and TSC-
LAM) according to serum MMP7 
 
 MMP-7 < 50° percentile MMP-7 ≥ 50° percentile P 
FEV1, % pred 98 (84-113) 95 (84-102) 0.314 
FVC, % pred 98 (82-112) 95 (83-107) 0.282 
FEV1/FVC, % pred 100 (94-103) 101 (99-104) 0.173 
DLCO, % pred 81 (64-86) 70 (58-80) 0.002 
KCO, % pred 77 (67-94) 76 (66-85) 0.705 
VA, % pred 104 (96-122) 94 (82-110) 0.105 
VR, % pred 89 (72-137) 87 (58-130) 0.863 
TLC, % pred 99 (86-115) 100 (87-112) 0.863 
RV/TLC, % pred 122 (105-139) 127 (94-152)  
TGV, % pred 81 (73-121) 91 (69-122) 0.463 
Radiological severity 
Grade 0, n (%) 0 (0) 6 (32) 
 
0.033 
Grade I, n (%) 6 (67) 6 (32) 
Grade II, n (%) 0 (0) 5 (26) 
Grade III, n (%) 3 (33) 2 (11) 
 
*% Data and percentage referred to 28 patients with revised CT scan. FEV1: forced expiratory volume in one second; FVC: forced expiratory 
volume; DLCO: diffusion capacity for CO; VA: alveolar volume; TLC: total lung capacity; RV: residual volume; TGV: thoracic gas volume; %pred: 
% of predicted value. p < 0.050 in bold. 
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